


normalized bonds :
 1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12

Match level :
 1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
 11:Atom 12:Atom 13:Atom
 Element Count :
 Node 13: Limited
 C,C3-5
 N,N1-3

L1 STRUCTURE UPLOADED

=> d 11
 L1 HAS NO ANSWERS
 L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s 11
 SAMPLE SEARCH INITIATED 10:11:10 FILE 'REGISTRY'
 SAMPLE SCREEN SEARCH COMPLETED - 1241 TO ITERATE
 100.0% PROCESSED 1241 ITERATIONS 9 ANSWERS
 SEARCH TIME: 00.00.01
 FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**
 PROJECTED ITERATIONS: 22707 TO 26933
 PROJECTED ANSWERS: 9 TO 360

L2 9 SEA SSS SAM L1

=> s 11 sss full
 FULL SEARCH INITIATED 10:11:18 FILE 'REGISTRY'
 FULL SCREEN SEARCH COMPLETED - 23846 TO ITERATE

100.0% PROCESSED 23846 ITERATIONS
SEARCH TIME: 00.00.01

258 ANSWERS

L3 258 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS
FULL ESTIMATED COST

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	166.94	167.15

FILE 'CAPLUS' ENTERED AT 10:11:24 ON 11 SEP 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 11 Sep 2006 VOL 145 ISS 12
FILE LAST UPDATED: 10 Sep 2006 (20060910/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 13
L4 30 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2006437532 CAPLUS
 DOCUMENT NUMBER: 144:468184
 TITLE: Pyridazine compounds as modulators of cellular pathways, their preparation, pharmaceutical compositions, and use in therapy
 INVENTOR(S): Watterson, D. Martin; Van Elstik, Linda; Haisch, Jacques; Hibert, Marcel; Bourguignon, Jean-Jacques; Valente, Anaesthesia; Hu, Wenhui; Zasiedzki, Magdalena
 PATENT ASSIGNEE(S): Northwestern University, USA; Universite' Louis Pasteur de Strasbourg
 SOURCE: PCT Int. Appl., 236 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006050389	A2	20060511	WO 2005-US39541	20051102
WO 2006050389	A3	20060511		
W: AM, AG, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MX, MW, MX, M2, M4, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TH, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZV	RW: AT, BE, BG, CH, CY, CZ, DE, DX, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TH	PRIORITY APPLN. INFO.:	US 2004-624346P	P 20041102
			US 2005-723080P	P 20051003
			US 2005-723124P	P 20051003

OTHER SOURCE(S): MARPAT 144:468184
 GI


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to pyridazines and related compds. of formulas I or II, which are modulators of cellular pathways. In compds. I and II, R1, R2, and R3 are independently selected from H, OH, alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, aryl, heteroaryl, heterocyclyl, etc., or R1 and R2 or R2 and R3 may form a fused heteroaryl or heterocyclyl ring; R4, R5, and R6 are independently selected from H, halo, nitro, alkyl, and alkynyl, and R7 is H, OH, alkyl, alkenyl, alkynyl, aryl, alkoxy, heteroaryl, heterocyclyl, etc., or R1 and R7 may form a fused heteroaryl or heterocyclyl ring; including isomers and pharmaceutically acceptable salts thereof. The invention also relates to the preparation of I and II, pharmaceutical compns.

L4 ANSWER 1 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 comprising a compd. I or II and a pharmaceutically acceptable carrier, excipient, or vehicle, as well as to the use of the compns. for the treatment or prevention of inflammatory diseases, such as Alzheimer's disease. Substitution of 3-chloro-4-hydroxypyridazine with 1-(pyrimidin-2-yl)piperazine gave hydroxypyridazine III, which underwent chlorination and Suzuki coupling with phenylboronic acid to give pyridazine IV. Compd. IV expressed 91% inhibition of hERG (human ether-a-go-go related gene) potassium ion channel binding.

IT 886208-6-S*, 4-(4-Pyridinyl)-3-phenyl-6-(4-(pyrimidin-2-yl)piperazin-1-yl)pyridazine
 NL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses); (Drug candidate, preparation of pyridazines as modulators of cellular signalling pathways)

RN 886208-63-5 CAPLUS
 CN Pyridazine, 3-phenyl-4-(4-pyridinyl)-6-[4-(2-pyrimidinyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 2 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2005-611823 CAPLUS
 DOCUMENT NUMBER: 143:153709
 TITLE: Synthesis of macrocyclic hepatitis C virus (HCV) serine protease NS3 inhibitors
 INVENTOR(S): Miao, Zhenwei; Sun, Ying; Nakajima, Suannes; Tang, Datong; Wu, Frank; Xu, Guoyou; Orl, Yat S.; Wang, Zhe
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 229 pp.
 CODEN: USXKCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005153877	A1	20050714	US 2004-774047	20040206
PRIORITY APPLN. INFO.:			US 2003-509069P	P 20030213
OTHER SOURCE(S):	MARPAT 143:153709			
GI				




AB The invention relates to cyclic peptides I [A = H, COR2, CO2R1, CONHR2, etc., G = OH, alkoxy, NH5O2R1, CO2R1, CONHR1, etc., L = absent, S, SO2, O, COCH2, CF2CH2, etc.; j = 0-4; n, s = 0-2; R1, R2 = H, C1-6-alkyl, (substituted)aryl, heteroaryl, etc.; R3, R4 = H, OH, Me, CN, SH, halo, NO2, NH2, amide, MeO, CF3O, CF3; E = CH:CH, CH2CH2; V = (un)substituted heterocyclic ring, or their pharmaceutically-acceptable salts, esters, or prodrugs, which inhibit serine protease activity, particularly the activity of HCV NS3-NS4A protease. An example is I [A = Me3CO2C, G = OH, L = absent, W = 5-phenyl-1,2,3,4-tetrazol-2-yl, j = 3, m, s = 1; R3, R4 = H], which was prepared via peptide coupling and ring-closing metathesis.


IT 220967-35-1
 RL: RCT (Reactant), RACT (Reactant or reagent)
 (synthesis of macrocyclic hepatitis C virus (HCV) serine protease NS3 inhibitors)

RN 220967-35-1 CAPLUS
 CN 3(2H)-Pyridazinone, 6-phenyl-5-(1-piperidinyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L4 ANSWER 3 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2005:510504 CAPLUS
 DOCUMENT NUMBER: 143:193877
 TITLE: Synthesis and SAR of 2,3-diarylpyrrole inhibitors of parasite cGMP-dependent protein kinase as novel anticooccidial agents
 AUTHOR(S): Biftu, Tesfaye; Feng, Dennis; Poppicom, Mitree; Girotra, Narinder; Liang, Gui-Bai; Qian, Xiaowei; Bugianesi, Robert; Simeone, Joseph; Chang, Linda; Gurnett, Anna; Liberator, Paula; Dulski, Paula; Leavitt, Jenny Sue; Crumley, Tam; Misra, Andrew; Murphy, Terence; Matray, Sandra; Samaras, Samantha; Tamas, Tamara; Mathew, John; Brown, Christine; Thompson, Don; Schmatz, Dennis; Fisher, Michael; Wyvatt, Matthew
 CORPORATE SOURCE: Merck Research Laboratories, Department of Medicinal Chemistry, Merck and Co., Rahway, NJ, 07065-0900, USA
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2005), 15(13), 3296-3301
 CODEN: BMCLB8; ISSN: 0960-894X
 PUBLISHER: Elsevier B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 143:193877
 GI




AB Several analogs of 2,3-diarylpyrroles, e.g., I, were synthesized and evaluated as inhibitors of *Plasmodium falciparum* cGMP-dependent protein kinase and in *in vivo* anticooccidial assays. The 4-fluorophenyl group enhanced both *in vitro* and *in vivo* activities. The most potent analogs were the 5-(N-Me, N-Et, and N-methylazetidine methyl) piperidyl deriva. These compounds have a broad spectrum of activity. Based on the *in vivo* efficacy and cost of synthesis, the N-Et analog I was chosen as an anticooccidial agent for a field trial.


IT 861804-58-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prep, parasite cGMP-dependent protein kinase binding affinity, anticooccidial activity, and structure-activity relationship of diarylpyrroles, pyridinyl(fluorophenyl)imidazole, -furan, -thiophene, -oxazole, -thiazole, and -pyridazine)
 RN 861804-58-2 CAPLUS
 CN 1-Piperidin-3-carboxylic acid, 4-[6-(4-fluorophenyl)-5-(4-pyridinyl)-3-pyridazinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

RN 861804-26-4 CAPLUS

L4 ANSWER 3 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN Pyridazine, 3-(4-fluorophenyl)-6-(1-methyl-4-piperidinyl)-4-(4-pyridinyl)- (9CI) (CA INDEX NAME)




IT 861804-58-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prep, parasite cGMP-dependent protein kinase binding affinity, anticooccidial activity, and structure-activity relationship of diarylpyrroles, pyridinyl(fluorophenyl)imidazole, -furan, -thiophene, -oxazole, -thiazole, and -pyridazine)
 RN 861804-58-2 CAPLUS
 CN 1-Piperidin-3-carboxylic acid, 4-[6-(4-fluorophenyl)-5-(4-pyridinyl)-3-pyridazinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2005:321950 CAPLUS
 DOCUMENT NUMBER: 143:43843
 TITLE: Design and synthesis of potent pyridazine inhibitors of p38 MAP kinase
 AUTHOR(S): Tamayo, Nuria; Liso, Lillian; Goldberg, Martin; Powers, David; Tudor, Yan-Yan; Yu, Violeta; Wong, Lu; Min, Henkle, Bradley; Middleton, Scott; Syed, Rashid; Harvey, Timothy; Jang, Graham; Hungate, Randall; Dominguez, Celio
 CORPORATE SOURCE: Chemistry Research and Discovery, Amgen, Inc., Thousand Oaks, CA, 91320, USA
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2005), 15(9), 2409-2413
 CODEN: BMCLB8; ISSN: 0960-894X
 PUBLISHER: Elsevier B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 143:43843
 AB Novel potent tri-substituted pyridazine inhibitors of p38 MAP (mitogen activated protein) kinase are described that have activity in both cell-based assays of cytokine release and animal models of rheumatoid arthritis. They demonstrated potent inhibition of LPS-induced TNF- α production in mice and exhibited good efficacy in the rat collagen induced arthritis model.
 IT 853730-50-4P
 RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
 (design and synthesis of potent pyridazine inhibitors of p38 MAP kinase)
 RN 853730-50-4 CAPLUS
 CN Pyridazine, 3-(2-naphthalenyl)-6-[(3R)-3-(phenylmethyl)-1-piperazinyl]-4-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 271247-18-8P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
 (design and synthesis of potent pyridazine inhibitors of p38 MAP kinase)
 RN 271247-18-8 CAPLUS
 CN 2-Pyridinamine, N-[(1S)-1-phenylethyl]-4-[6-(4-piperidinyl)-3-(trifluoromethyl)phenyl]-4-pyridazinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Habte

L4 ANSWER 4 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



IT 271247-22-4P 853730-36-6P 853730-37-7P
 853730-38-8P 853730-39-9P 853730-43-5P
 853730-44-6P 853730-45-7P 853730-46-8P
 853730-47-9P 853730-48-0P 853730-49-1P
 853730-51-5P 853730-52-6P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (design and synthesis of potent pyridazine inhibitors of p38 MAP kinase)
 RN 271247-22-4 CAPLUS
 CN 2-Pyridinamine, N-[(1S)-1-phenylethyl]-4-[6-(4-piperidinyl)-3-(trifluoromethyl)phenyl]-4-pyridazinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 853730-36-6 CAPLUS

09/11/2006

L4 ANSWER 4 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN Benzamide, N-methyl-N-[4-[6-(4-piperidinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 853730-37-7 CAPLUS
 CN Benzamide, 4-fluoro-N-methyl-N-[4-[6-(4-piperidinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 853730-38-8 CAPLUS
 CN 2-Pyrimidinamine, N-[1-(4-fluorophenyl)ethyl]-4-[6-(4-piperidinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 4 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 853730-39-9 CAPLUS
 CN Piperidine, 1-[(2R)-2-hydroxy-1-exopropyl]-4-[5-[2-[(1S)-1-phenylethyl]amino]-4-pyridinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




L4 ANSWER 4 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A


OH

RN 853730-43-5 CAPLUS
 CN 1,2-Propanediamine, 3-phenyl-N1-[5-(4-pyrimidinyl)-6-(3-(trifluoromethyl)phenyl)-3-pyridazinyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry:




RN 853730-44-6 CAPLUS
 CN 1,2-Propanediamine, 2-methyl-3-phenyl-N1-[5-(4-pyrimidinyl)-6-(3-(trifluoromethyl)phenyl)-3-pyridazinyl]- (9CI) (CA INDEX NAME)



RN 853730-45-7 CAPLUS
 CN 1,2-Propanediamine, N1-[6-(2-naphthalenyl)-5-(4-pyridinyl)-3-pyridazinyl]-3-phenyl-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 4 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 853730-46-8 CAPLUS
 CN 1,2-Propanediamine, 3-(4-fluorophenyl)-N1-[6-(2-naphthalenyl)-5-(4-pyridinyl)-3-pyridazinyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 853730-47-9 CAPLUS
 CN 1,2-Propanediamine, N2-(1-methylethyl)-N1-[6-(2-naphthalenyl)-5-(4-pyridinyl)-3-pyridazinyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 853730-48-0 CAPLUS
 CN 3-Pyridazinamine, 6-(2-naphthalenyl)-N-[2R)-3-phenyl-2-(1-pyrrolidinyl)propyl]-5-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 4 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN

(Continued)




RN 853730-49-1 CAPLUS
 CN Acetamide, 2-hydroxy-N-[(1R)-1-[[[6-(2-naphthalenyl)-5-(4-pyridinyl)-3-pyridazinyl]amino]methyl]-2-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 853730-51-5 CAPLUS
 CN Pyridazine, 6-[(3R)-3-(2-methylpropyl)-1-piperazinyl]-3-(2-naphthalenyl)-4-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 853730-52-6 CAPLUS
 CN Piperazine, 1-(hydroxymethyl)-4-[6-(2-naphthalenyl)-5-(4-pyridinyl)-3-pyridazinyl]-2-(phenylmethyl)-, (2R)- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 Absolute stereochemistry.


IT 271247-34-8P 271247-35-9P 271247-36-0P
 271247-42-8P 271247-43-9P 629623-79-5P
 629623-79-6P 853730-34-4P 853730-35-5P
 853730-41-3P 853730-42-4P
 RL RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (design and synthesis of potent pyridazine inhibitors of p38 MAP kinase)

RN 271247-34-8 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[5-[2-(methylthio)-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 271247-35-9 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[5-[2-(methylsulfonyl)-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 271247-36-0 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[5-[2-[(1S)-1-phenylethyl]amino]-4-pyridinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 271247-42-8 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[5-(2-fluoro-4-pyridinyl)-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 271247-43-9 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[5-[2-[(1S)-1-phenylethyl]amino]-4-pyridinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 629623-78-5 CAPLUS
 CN 3(2H)-Pyridazinone, 6-(2-naphthalenyl)-5-(4-pyridinyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 4 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 629623-79-6 CAPLUS
 CN Pyridazine, 6-chloro-3-(2-naphthalenyl)-4-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 853730-34-4 CAPLUS
 CN 1-Piperidinocarboxylic acid, 4-[5-[2-(methylamino)-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 853730-35-5 CAPLUS
 CN 1-Piperidinocarboxylic acid, 4-[5-[2-[1-(4-fluorophenyl)ethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl-, phenylmethyl

L4 ANSWER 4 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 ester (9CI) (CA INDEX NAME)

RN 853730-41-3 CAPLUS
 CN 3(2H)-pyridazinone, 5-(4-pyrimidinyl)-6-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 853730-42-4 CAPLUS
 CN Pyridazine, 6-chloro-4-(4-pyrimidinyl)-3-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 4 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2004-1927172 CAPLUS
 DOCUMENT NUMBER: 141:395567

TITLE: Preparation of substituted pyridazines and analogs for treatment of TNF- α , IL-1 β , IL-6, and/or IL-8 mediated disorders

INVENTOR(S): Dominguez, Celia; Goldberg, Martin H.; Tamayo, Nuria A.

PATENT ASSIGNEE(S): Amgen Inc., USA
 SOURCE: PCT Int. Appl., 46 pp.

CODEN: PIXX02

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004094379	A2	20041104	WO 2004-US11953	20040415
WO 2004094379	A3	20050331		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DR, DX, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KO, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZR, ZW, BY, GH, GN, KE, LS, MW, MZ, SD, SL, SZ, T2, UG, ZH, ZR, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BE, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, HL, MA, NE, SN, TD, TG				
US 2004254178	A1	20041216	US 2004-826982	20040415
EP 1620665	A2	20060301	EP 2004-750293	20040415
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
PRIORITY APPLN. INFO.: US 2003-463697P			P 20030415	
OTHER SOURCE(S): MARPAT 141:395567			WO 2004-US11953	W 20040415

L4 ANSWER 5 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




AB Title compds. I [wherein X1, X2 = independently (un)substituted CH, N; with the proviso that at least one of X1 and X2 = N; R1 = (Halo)alkyl, CN, NO₂, acyl, carboxy, carbamoyl, alkoy, sulfamoyl, ureido, etc.; R2 = alkyl, Ph, PhCH₂, heterocyclyl, etc.; R3, R4 = independently (un)substituted Ph, naphthyl, heterocyclyl, or pharmaceutically acceptable salts thereof] were prepared as TNF-, IL-6, and/or IL-8 inhibitors. For example, a multi-step synthesis concluding with the reaction of 4-(2-methanesulfonyl)pyrimidin-4-yl)-4-methyl-6-(3-trifluoromethylphenyl)pyridazin-3-yl)piperidine-1-carboxylic acid benzyl ester and (S)-(-)-1-phenylethylamine gave II. The latter inhibited lipopolysaccharide-activated THP1 cell TNF- production with IC₅₀ < 20 μM. Thus, I and their pharmaceutical compns. are useful for the treatment of inflammation, rheumatoid arthritis, Paget's disease, osteoporosis, multiple myeloma, uveitis, acute or chronic myelogenous leukemia, pancreatic b cell destruction, osteoarthritis, rheumatoid spondylitis, gouty arthritis, inflammatory bowel disease, adult respiratory distress syndrome (ARDS), psoriasis, Crohn's disease, allergic rhinitis, ulcerative colitis, anaphylaxis, contact dermatitis, asthma, muscle degeneration, cachexia, Reiter's syndrome, type I diabetes, type II diabetes, bone resorption diseases, graft vs. host reaction, Alzheimer's disease, stroke, myocardial infarction, ischemia reperfusion injury, atherosclerosis, brain trauma, multiple sclerosis, cerebral malacia, sepsis, septic shock, toxic shock syndrome, fever, myalgia due to HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus; the herpes viruses, or herpes zoster infection (no date).

IT 786705-13-3P, 4-[4-Methyl-5-(2-methysulfonyl)pyrimidin-4-yl]-6-(3-trifluoromethylphenyl)pyridazin-3-yl)piperidine-1-carboxylic acid benzyl ester 786705-15-SP, 4-[5-(2-Methysulfonyl)pyrimidin-4-yl]-4-methyl-6-(3-trifluoromethylphenyl)pyridazin-3-yl)piperidine-1-carboxylic acid benzyl ester 786705-17-7P, 4-[4-Methyl-5-(2-1-phenylethylamino)pyrimidin-4-yl]-6-(3-trifluoromethylphenyl)pyridazin-3-yl)piperidine-1-carboxylic acid benzyl ester 786705-19-9P,


L4 ANSWER 5 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 2-Hydroxy-1-[4-(4-methyl-5-[2-(1-phenylethylamino)pyrimidin-4-yl]-6-(3-trifluoromethylphenyl)pyridazin-3-yl)piperidine-1-yl]propan-1-one 786705-23-5P, (S)-4-[4-Methyl-5-(2-(1-phenylethylamino)pyrimidin-4-yl)-6-(3-trifluoromethylphenyl)pyridazin-3-yl)piperidine-1-carboxylic acid benzyl ester 786705-25-7P, [4-[5-Methyl-6-(piperidin-4-yl)-3-(3-trifluoromethylphenyl)pyridazin-4-yl]pyrimidin-2-yl] (S)-1-phenylethylamine 786705-27-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses); (TNF and/or IL inhibitor; prepn. of substituted pyridazines and analogs as TNF and IL inhibitors for treatment inflammation, pain, and other disorders)

RN 786705-13-3 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[4-methyl-5-[2-(methylthio)-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 786705-15-5 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[4-methyl-5-[2-(methylsulfonyl)-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 786705-17-7 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[4-methyl-5-[2-(1-phenylethylamino)-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 786705-19-9 CAPLUS
CN 2-Pyrimidinamine, 4-[5-methyl-6-(4-piperidinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-(1-phenylethyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 786705-21-3 CAPLUS
CN Piperidine, 1-[2-hydroxy-1-oxopropyl]-4-[4-methyl-5-[2-(1-phenylethylamino)-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]- (9CI) (CA INDEX NAME)



RN 786705-23-5 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[4-methyl-5-[2-[(1S)-1-phenylethylamino)-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 5 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 786705-25-7 CAPLUS
 CN 2-Pyrimidinamine, 4-[5-methyl-6-(4-piperidinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl] - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 786705-27-9 CAPLUS
 CN Piperidine, 1-[(2R)-2-hydroxy-1-oxopropyl]-4-[4-methyl-5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-6-(3-(trifluoromethyl)phenyl)-3-

L4 ANSWER 5 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 pyridazinyl) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 2-A

L4 ANSWER 6 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2004:698218 CAPLUS
 DOCUMENT NUMBER: 141:220883
 TITLE: Macrocyclic hepatitis C virus (HCV) serine protease NS3 inhibitors, their synthesis and use to prevent HCV infection
 INVENTOR(S): Miao, Zewei; Sun, Ying; Wu, Frank; Nakajima, Suanne; Xu, Guoyou; Or, Yat Sun; Wang, Zhe
 PATENT ASSIGNEE(S): Enanta Pharmaceuticals, Inc., USA
 SOURCE: PCT Int. Appl., 299 pp.
 DOCUMENT TYPE: CODEN: PIXXD2
 LANGUAGE: Patent
 FAMILY ACC. NUM. COUNT: English 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004072243	A2	20040826	WO 2004-US3479	20040206
WO 2004072243	A3	20051103		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KE, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, RW, BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004180815	A1	20040916	US 2003-384120	20030307
AU 2004211637	A1	20040826	AU 2004-211637	20040206
CA 2515216	AA	20040826	CA 2004-2515216	20040206
EP 1590442	A2	20051102	EP 2004-709020	20040206
EP 1590442	A3	20051221		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1771050	A	20060510	CN 2004-80009268	20040206
PRIORITY APPLN. INFO. :				
			US 2003-360947	A 20030207
			US 2003-365854	A 20030213
			US 2003-384120	A 20030307
			WO 2004-US3479	A 20040206

OTHER SOURCE(S): MARPAT 141:220883
 GI


AB The present invention relates to compds. I [A = H, COR2, COOR1, CONHR2,

Habte

09/11/2006


L4 ANSWER 6 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 etc.; G = OH, COR2, COOR1, CONHR1, etc.; L = S, SO2, O, COCH2, CF2CH2, etc.; j = 0-4; m, n = 0-2; R1,R2 = H, Cl-6-alkyl, (substituted)aryl, heteroaryl, etc.; R3,R4 = H, OH, Me, CN, SH, halo, NO2, NH2, amide, MeO, CF3O, CF3; E = CH:CH, CH2CH2; V = (un)substituted heterocyclic ring, or a pharmaceutically acceptable salt, ester, or prodrug thereof, and to methods for their synthesis. The compds. inhibit serine protease activity, particularly the activity of HCV NS3-NS4A protease. Consequently, the compds. of the present invention interfere with the life cycle of HCV and are also useful as antiviral agents. The present invention further relates to pharmaceutical compns. comprising the aforementioned compds. for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical compn. comprising the compds. of the present invention.

IT 220967-35-1

RL: RCT (Reactant); RACT (Reactant or reagent)
 (macrocyclic hepatitis C virus (HCV) serine protease NS3 inhibitors, their synthesis and use to prevent HCV infection)RN 220967-35-1 CAPLUS
 CN 3(2H)-Pyridazinone, 6-phenyl-5-(1-piperidinyl) - (9CI) (CA INDEX NAME)

L4 ANSWER 7 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 20031951017 CAPLUS
 DOCUMENT NUMBER: 140:16737
 TITLE: Preparation of substituted heterocyclic compounds as inhibitors of TNF- α
 INVENTOR(S): Dominguez, Celisa; Zhang, Dawei; Cao, Guo-Qiang;
 Goldberg, Martin H.; Hong, Fang-Tsao; Sham, Kelvin K.
 C.; Tadesse, Seifu; Tamayo, Nuria A.; Weiler, Kurt E.;
 Liao, Hongyu
 PATENT ASSIGNEE(S): Amgen Inc., USA
 SOURCE: PCT Int. Appl., 97 pp.
 CODEN: PIXKD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PRIORITY INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003099808	A1	20031204	WO 2003-US15473	20030515
W: AE, AG, AL, AM, AT, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KS, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, C2, DE, EE, ES, FI, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BY, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2485166	AA	20031204	CA 2003-2485166	20030513
US 2005038010	A1	20050217	US 2003-438553	20030513
US 7026326	B2	20060411		
AU 2003234628	A1	20031212	AU 2003-234628	20030515
EP 1506186	A1	20050216	EP 2003-728971	20030515
R: AT, BE, CH, DK, ES, FR, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, C2, EE, HU, SK				
JP 2005530810	T2	20051013	JP 2004-507465	20030515
PRIORITY APPLN. INFO.:			US 2002-382699P	P 20020521
OTHER SOURCE(S):	MARPAT 140:16737		WO 2003-US15473	W 20030515
GI				



L4 ANSWER 7 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 629623-79-6 CAPLUS
 CN Pyridazine, 6-chloro-3-(2-naphthalenyl)-4-(4-pyridinyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


AB Title compds. I [R1 = (un)saturated 5-7 membered, optionally benzo-fused, (hetero)cycle; R2 = alkyl, etc.; R3-4 = (un)substituted R]; R5 = aryl, (un)saturated 5-7 membered, optionally benzo-fused heterocycle; X, V, W = N; NR5, CR6, C10, etc.; R6 = H, alkyl; R7 = alkyl] are prepared. For instance, (R)-2-aminoethylpyrrolidine-1-carboxylic acid tert-Bu ester (preparation given) is deprotected (dioxane, HCl) and reacted with 2-chloro-5-(4-chlorophenyl)-3-methyl-6-(pyridin-4-yl)-3H-pyrimidin-4-one (K2CO3) to give II as a yellow solid. Example compds. exhibit activities in the THP cell assay (IL-8 induced TNF release) with IC50 of 20 μ M or less. I are useful in the treatment of inflammation, rheumatoid arthritis, Pagets disease, etc.

IT RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses); (substituted pyridine/pyrimidine analogs as inhibitors of TNF- α)

RN 629623-49-0 CAPLUS

CN 2-Pyrrolidinemethanamine, N-(1-methylethyl)-1-[6-(2-naphthalenyl)-5-(4-pyridinyl)-3-pyridazinyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 629623-78-5P 629623-79-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent); (substituted pyridine/pyrimidine analogs as inhibitors of TNF- α)

RN 629623-78-5 CAPLUS

CN 3(2H)-Pyridazinone, 6-(2-naphthalenyl)-5-(4-pyridinyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 8 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002849596 CAPLUS

DOCUMENT NUMBER: 137:370099

TITLE: Preparation of 3-aminopyrazolo[3,4-c]pyridazines as inhibitors of glycogen synthase kinase-3 and crystal structures of gsk-3 β protein and protein complexes

INVENTOR(S): Ter Haar, Ernst; Svensson, Lovorka; Green, Jeremy; Arnst, Michael J.

PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA

SOURCE: PCT Int. Appl., 778 pp.

CODEN: PIXKD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002088078	A2	20021107	WO 2002-US13511	20020429
WO 2002088078	A3	20040506		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, C2, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2444882	AA	20021107	CA 2002-2444882	20020429
AU 2002259071	A1	20021111	AU 2002-259071	20020429
US 2003125332	A1	20030703	US 2002-135255	20020429
EP 1435957	A2	20040714	EP 2002-729056	20020429
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2005504731	T2	20050217	JP 2002-585380	20020429
PRIORITY APPLN. INFO.:			US 2001-287366P	P 20010430
			US 2001-297094P	P 20010608
			US 2002-361899P	P 20020227
OTHER SOURCE(S):	MARPAT 137:370099		WO 2002-US13511	W 20020429



AB Title compds. I [R1 = H, RCO, RO₂C, (substituted) aliphatic, carbocyclic, heterocyclic, etc.; R2, R3 = H, (substituted) aliphatic, carbocyclic, heterocyclic, aryl, aralkyl, heteroaryl, heteroaralkyl, NR2,


L4 ANSWER 8 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 NRCOR, SR, OR, CF₃, halo, NO₂, cyano, etc., R = H, (substituted) aliphatic, carbocyclic, heterocyclic, aryl, aralkyl, heteroaryl, heteroaralkyl, were prep'd. Thus, 3-chloro-4-cyano-5,6-diphenylpyridazine was refluxed with NH₂H in EtOH to give 3-amino-4,5-diphenyl-1H-pyrazolo[3,4-c]pyridazine. The latter inhibited gsk-3 with Ki≤0.1 μM.

IT 474380-93-3P 474380-94-4P 474380-95-5P
 474381-17-4P 474381-19-6P 474381-25-4P
 474381-27-6P 474381-33-4P 474381-35-6P
 474381-66-3P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses); (preparation of pyrazolopyridazines as inhibitors of gsk-3 and crystal structures of gsk-3B protein and protein complexes)

RN 474380-93-3 CAPLUS
 CN 1H-Pyrazolo[3,4-c]pyridazin-3-amine

(CA INDEX NAME)




RN 474380-94-4 CAPLUS
 CN 1H-Pyrazolo[3,4-c]pyridazin-3-amine, 5-phenyl-4-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 474380-95-5 CAPLUS
 CN 1H-Pyrazolo[3,4-c]pyridazin-3-amine, 5-phenyl-4-(4-pyridinyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 8 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 474381-17-4 CAPLUS
 CN 1H-Pyrazolo[3,4-c]pyridazin-3-amine, 5-(2-chlorophenyl)-4-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 474381-19-6 CAPLUS
 CN 1H-Pyrazolo[3,4-c]pyridazin-3-amine, 5-(2-chlorophenyl)-4-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 474381-25-4 CAPLUS
 CN 1H-Pyrazolo[3,4-c]pyridazin-3-amine, 5-(3-methoxyphenyl)-4-(4-pyridinyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 8 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 474381-27-6 CAPLUS
 CN 1H-Pyrazolo[3,4-c]pyridazin-3-amine, 5-(3-methoxyphenyl)-4-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 474381-33-4 CAPLUS
 CN 1H-Pyrazolo[3,4-c]pyridazin-3-amine, 5-(4-methylphenyl)-4-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 474381-35-6 CAPLUS
 CN 1H-Pyrazolo[3,4-c]pyridazin-3-amine, 5-(4-methylphenyl)-4-(3-pyridinyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 8 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 474381-66-3 CAPLUS
 CN 1H-Pyrazolo[3,4-c]pyridazin-3-amine, 4-[2-(methylthio)-4-pyrimidinyl]-5-phenyl- (9CI) (CA INDEX NAME)



L4 ANSWER 9 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2002:509086 CAPLUS
 DOCUMENT NUMBER: 137:337849
 TITLE: Pyridazine derivatives. XXIV. Efficient N-methylation of diversely substituted 3(2H)-pyridazinones using N,N-dimethylformamide dimethylacetal
 AUTHOR(S): Sotalo, Eddy; Rayna, Enciso
 CORPORATE SOURCE: Departamento de Química Orgánica, Laboratorio de Química Farmacéutica, Facultad de Farmacia, Universidad de Santiago de Compostela, Santiago de Compostela, 15782, Spain
 SOURCE: Synthetic Communications (2002), 32(11), 1675-1680
 PUBLISHER: Marcel Dekker, Inc.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 137:337848
 GI




AB A series of diversely substituted 3(2H)-pyridazinones, e.g., I, were efficiently N-methylated at position 2 by treatment with N,N-dimethylformamide dimethylacetal in DMF.

IT 220967-35-1
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of methylated pyridazinones via N-methylation of pyridazinones with N,N-dimethylformamide dimethylacetal)

RN 220967-35-1 CAPLUS

CN 3(2H)-Pyridazinone, 6-phenyl-5-(1-piperidinyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE' FORMAT

L4 ANSWER 10 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2002:116979 CAPLUS
 DOCUMENT NUMBER: 137:125130
 TITLE: Pyridazine based inhibitors of p38 MAPK
 AUTHOR(S): McIntyre, Charles J.; Ponticello, Gerald S.; Liverton, Nigel J.; O'Keefe, Stephen J.; O'Neill, Edward A.; Pang, Margaret; Schwartz, Cheryl D.; Claremon, David A.
 CORPORATE SOURCE: Department of Medicinal Chemistry, Merck Research Laboratories, West Point, PA, 19486, USA
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2002), 12(4), 689-692
 PUBLISHER: Elsevier Science Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 137:125130


AB Tributylsubstituted pyridazines were synthesized and evaluated as in vitro inhibitors of p38 MAPK. The most active isomers were those possessing an aryl group α - and a heteroaryl group β relative to the nitrogen atom in the 2-position of the central pyridazine. Addnl. substitution in the 6-position of the central pyridazine with a variety of dialkylamino substituents afforded a set of inhibitors having good (p38 IC₅₀ 1-20 nM) in vitro activity.

IT 271247-37-1P 443958-06-9P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation of pyridazine based inhibitors of p38 MAPK)

RN 271247-37-1 CAPLUS


CN 2-Pyrimidinamine, N-[(1S)-1-phenylethyl]-4-[6-(4-piperidinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 10 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 443958-06-9 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-(4-morpholinyl)-3-(3-(trifluoromethyl)phenyl)-4-pyridazinyl]-N-[(1S)-1-phenylethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 271247-18-8P 271247-34-8P 271247-35-9P
 271247-36-0P 344465-97-0P 344465-98-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of pyridazine based inhibitors of p38 MAPK)
 RN 271247-18-8 CAPLUS
 CN 2-Pyrimidinamine, N-[(1S)-1-phenylethyl]-4-[6-(4-piperidinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L4 ANSWER 10 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 271247-34-8 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[5-[2-(methylthio)-4-pyridinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 271247-35-9 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[5-[2-(methylsulfonyl)-4-pyridinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 271247-36-0 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[5-[2-((1S)-1-phenylethyl)amino]-4-pyridinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 10 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN

(Continued)



RN 344465-97-0 CAPLUS
 CN 3-(2H)-Pyridazinone, 5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-6-(3-(trifluoromethyl)phenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 344465-98-1 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-chloro-3-(3-(trifluoromethyl)phenyl)-4-pyridazinyl]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 10 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



IT 344464-67-1P 344464-93-1P 344464-94-2P
 344464-91-1P 344464-93-3P 344464-96-6P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of pyridazine based inhibitors of p38 MAPK)
 RN 344464-67-1 CAPLUS
 CN 3-Pyridazinamine, N,N-dimethyl-5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-6-(3-(trifluoromethyl)phenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 344464-83-1 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-(4-methyl-1-piperazinyl)-3-(3-(trifluoromethyl)phenyl)-4-pyridazinyl]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 10 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 344464-84-2 CAPLUS
 CN 2-Pyrimidinamine, N-[(1S)-1-phenylethyl]-4-[6-(1-piperazinyl)-3-(3-(trifluoromethyl)phenyl)-4-pyridazinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 344464-91-1 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-(4-methyl-1-piperidinyl)-3-(3-(trifluoromethyl)phenyl)-4-pyridazinyl]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 10 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 344464-93-3 CAPLUS
 CN 1,2-Ethanediamine, N,N,N'-trimethyl-N'-[5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-6-(3-(trifluoromethyl)phenyl)-3-pyridazinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 344464-96-6 CAPLUS
 CN 2-Pyrimidinamine, N-[(1S)-1-phenylethyl]-4-[6-(1-piperidinyl)-3-(3-(trifluoromethyl)phenyl)-4-pyridazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 10 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2002:51440 CAPLUS
 DOCUMENT NUMBER: 136:102392
 TITLE: Preparation of phenylpyridazine derivatives as inhibitors of interleukin 1 β production
 INVENTOR(S): Oshuchi, Masa; Kyotani, Yoshinori; Shigyo, Hiromichi; Koshi, Tomoyuki; Ohgiya, Tadaaki; Matsuda, Takayuki; Kumai, Natsuyuki; Yasuoka, Kyoko
 Kowa Co., Ltd., Japan
 PCT Int. Appl., 70 EP.
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002004427	A1	20020117	WO 2001-JP5904	20010706
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KW, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TU, TM, TR, TT, TZ, UA, UG, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CL, CM, GA, GN, GV, ML, MR, NE, SN, TD, TG				
US 6664256	B1	20031216	US 2000-612953	20000710
CA 2413042	AA	20020117	CA 2001-2413042	20010706
AU 2001069474	A5	20020121	AU 2001-69474	20010706
EP 1300399	A1	20030409	EP 2001-947902	20010706
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
NZ 523242	A	20041029	NZ 2001-523242	20010706
RU 2269519	C2	20060210	RU 2003-103780	20010706
TW 593285	B	20040621	TW 2001-90116864	20010710
NO 2003000097	A	20030109	NO 2003-97	20030109
PRIORITY APPLN. INFO.:			US 2000-612953	A 20000710
OTHER SOURCE(S):	MARPAT 136:102392		WO 2001-JP5904	W 20010706

GI

L4 ANSWER 11 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




AB Compds. of the general formula (I) or salts thereof (wherein R1 is optionally substituted Ph or pyridyl; R2 is lower alkoxyl, lower alkylthio, lower alkylsulfinyl, or lower alkylsulfonyl; R3 is hydrogen or lower alkoxyl; or R2 and R3 together form a alkyleneoxy group; and R4 is hydrogen, halo, cyano, CO2H, each optionally substituted lower alkyl, lower alkenyl, lower alkylthio, lower alkylsulfinyl, lower alkylsulfonyl, lower alkylsulfonylonyl, aromatic hydrocarbyl, aromatic heterocyclyl, phenoxy, phenylthio, phenylsulfinyl, phenylsulfonyl, pyridyloxy, morpholino, morpholinocarbonyl, piperidinocarbonyl, 1-piperazinylcarbonyl, or NH2; n = 0, 1) are prepared. The compds. I exhibit an excellent interleukin 1 β production inhibiting activity and are useful as preventive and therapeutic drugs for diseases caused by increased production of interleukin 1 β such as immunol. diseases, inflammatory diseases, ischemic disease, osteoporosis, septicemia, rheumatism, arthritis, and inflammatory colitis. Thus, 2,3,4,5,6-pentafluorophenol and K2CO3 were added to a solution of 6-chloro-3-(4-methoxyphenyl)-4-phenylpyridazine in DMF and stirred at 80° for 7 to give 30.5% 3-(4-methoxyphenyl)-6-(2,3,4,5,6-pentafluorophenyl)-4-phenylpyridazine (II). II showed IC50 of 0.01 μ M for inhibiting the production of interleukin-1 β in HL-60 cells.

IT 388606-34-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of phenylpyridazine derivs. as inhibitors of interleukin 1 β production and preventive and therapeutic drugs for diseases caused by increased production of interleukin 1 β)

RN 388606-34-6 CAPLUS

CN Pyridazine, 6-(2,4-difluorophenoxy)-3-(4-methoxyphenyl)-4-(4-pyridinyl)- (9CI) (CA INDEX NAME)




IT 225666-37-5

Habte


L4 ANSWER 11 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RL: RCT (Reactant); RACT (Reactant or reagent)
 (prepn. of phenylpyridazine derivs. as inhibitors of interleukin 1 β prodn. and preventive and therapeutic drugs for diseases caused by increased prodn. of interleukin 1 β)
 RN 225666-37-5 CAPLUS
 CN 3(ZH)-Pyridazinone, 6-(4-methoxyphenyl)-5-(4-pyridinyl)- (9CI) (CA INDEX NAME)



IT 388606-33-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of phenylpyridazine derivs. as inhibitors of interleukin 1 β production and preventive and therapeutic drugs for diseases caused by increased production of interleukin 1 β)
 RN 388606-33-5 CAPLUS
 CN Pyridazine, 6-chloro-3-(4-methoxyphenyl)-4-(4-pyridinyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

09/11/2006

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001435072 CAPLUS

DOCUMENT NUMBER: 135:46188

TITLE: Substituted pyridazines having cytokine inhibitory activity

INVENTOR(S): McIntyre, Charles J.; Liverton, Nigel J.; Claremon, David A.

PATENT ASSIGNEE(S): Merck & Co., Inc., USA

SOURCE: PCT Int. Appl., 70 pp.

CODEN: PIXDZ

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001042241	A1	20010614	WO 2000-US33097	20001207
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MN, MV, MX, MS, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TH, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, IE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IT, LI, LU, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GW, ML, MR, ME, SM, TD, TG				
US 6602872	B1	20030805	US 2000-717277	20001121
CA 2392584	AA	20010614	CA 2000-2392584	20001207
EP 1240160	A1	20020918	EP 2000-986274	20001207
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MX, CY, AL, TR				
JP 2003517477	T2	20030527	JP 2001-543540	20001207
PRIORITY APPLN. INFO.:			US 1999-170319P	P 19991213
OTHER SOURCE(S): MARPAT 135:46188			WO 2000-US33097	W 20001207
GI				

US 6602872

CA 2392584


EP 1240160

JP 2003517477

PRIORITY APPLN. INFO.:

OTHER SOURCE(S): MARPAT 135:46188


GI



AB Pyridazines I [A is halogen, Ph, PhS(=O)m (m = 0-2), or R5R6N; R1 is H, alkylamino, or (un)substituted arylamino; R2, R3, R4 are independently halogen, hydroxy, F3C, amino, nitro, (Cl-C6)alkyl, (Cl-C6)alkoxy,

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A

RN 344464-73-9 CAPLUS

CN 2-Pyrimidinamine, N-[{(1S)-1-phenylethyl}-4-[6-(phenylthio)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 344464-66-0P 344464-67-1P 344464-68-2P
344464-69-3P 344464-71-7P 344464-72-8P

Habte

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
(C3-C8)cycloalkyl, Ph; R5 and R6 are independently hydrogen, alkoxy-, (un)substituted amino-, and (un)substituted phenyl-substituted (or unsubstituted) heterocycles; Q is CH or NJ are prep'd. as inhibitors or antagonists of the formation and activity of cytokines such as interleukin-1 β (IL-1 β), IL-6, and IL-8 for the treatment of cytokine mediated diseases and conditions such as inflammation, arthritis, sepsis and septic shock, osteoporosis, bone resorption diseases, and Crohn's disease. E.g., the dihydrochloride of I [A = Me2NCH2CH2NH; R1 = (S)-PhCH(Me)NH; R2 = 3-F3C; R3 = R4 = H] (II) was prep'd. by amidation of 3-trifluoromethylbenzoyl chloride with N-methoxymethyllithium, alkylation of the ketone with 2-(methylthio)-4-pyrimidinylmethyllithium, hydrolysis of the ester with hydrogen chloride in dioxane, addition and cyclization of the acid and ketone moieties with hydrazine, oxida. of the methylthio group to the pyrimidinyl Me sulfons with sodium tungstate and hydrogen peroxide, addn. of (S)- α -methylbenzylamine to the pyrimidinyl sulfone with substitution to give the pyrimidinamine, oxida. of the cyclic hydrazone to the hydroxypyridazine, and chlorination of the hydroxypyridazine with phosphorus oxychloride to give I [A = Cl; R1 = (S)-PhCH(Me)NH; R2 = 3-F3C; R3 = R4 = H] a key intermediate in the prepn. of the claimed pyridazines. E.g., treatment of I [A = Cl; R1 = (S)-PhCH(Me)NH; R2 = 3-F3C; R3 = R4 = H] with 2-(dimethylamino)ethylamine and heating at 100° gave II as the free base which was converted to the hydrochloride by treatment with 1N HCl. No biol. data is provided.

IT 344464-70-6P 344464-73-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

and activity for the treatment of cytokine-mediated diseases such as arthritis).

RN 344464-70-6 CAPLUS
CN Carbamic acid, [1-[5-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl-4-piperidinyl-, 1,1-dimethyl-ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

344464-74-0P 344464-75-1P 344464-76-2P

344464-77-3P 344464-78-4P 344464-79-5P

344464-80-8P 344464-81-9P 344464-82-0P

344464-83-1P 344464-84-2P 344464-85-3P

344464-86-4P 344464-87-5P 344464-88-6P

344464-89-7P 344464-90-0P 344464-91-1P

344464-92-2P 344464-93-3P 344464-94-4P

344464-95-5P 344464-96-6P 344464-97-7P

344464-98-8P 344464-99-9P 344465-00-5P

344465-01-6P 344465-02-7P 344465-03-8P

344465-04-9P 344465-05-0P 344465-06-1P

344465-07-2P 344465-08-3P 344465-09-4P

344465-10-7P 344465-11-8P 344465-12-9P

344465-13-0P 344465-14-1P 344465-15-2P

344465-16-3P 344465-17-4P 344465-18-5P

344465-19-6P 344465-20-9P 344465-21-0P

344465-22-1P 344465-23-2P 344465-24-3P

344465-25-4P 344465-26-5P 344465-27-6P

344465-28-7P 344465-29-8P 344465-31-2P

344465-33-4P 344465-34-5P 344465-35-6P

344465-36-7P 344465-37-8P 344465-38-9P

344465-40-3P 344465-42-5P 344465-44-7P

344465-46-9P 344465-48-1P 344465-50-5P

344465-52-7P 344465-53-8P 344465-54-9P

344465-55-0P 344465-56-1P 344465-57-2P

344465-58-3P 344465-59-4P 344465-60-7P

344465-61-8P 344465-62-9P 344465-63-0P

344465-64-1P 344465-65-2P 344465-66-3P

344465-67-4P 344465-68-5P 344465-69-6P

344465-70-9P 344465-71-0P 344465-72-1P

344465-73-2P 344465-74-3P 344465-75-4P

344465-76-5P 344465-77-6P 344465-78-7P

344465-79-8P 344465-80-1P 344465-81-2P

344465-82-3P 344465-83-4P 344465-84-5P

344465-85-6P 344465-86-7P 344465-87-8P

344465-88-9P 344465-89-0P 344465-90-3P

344465-91-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of pyridazine derivs. as inhibitors of cytokine formation and activity for the treatment of cytokine-mediated diseases such as arthritis).


RN 344464-66-0 CAPLUS

CN 1,2-Ethanediamine, N,N-dimethyl-N'-(5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl)-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

09/11/2006


L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



●2 HCl

RN 344464-67-1 CAPLUS
 CN 3-Pyridazinamine, N,N-dimethyl-5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 344464-68-2 CAPLUS
 CN 2-Pyridazinamine, 4-[6-(4-morpholinyl)-3-(trifluoromethyl)phenyl]-4-pyrimidinyl-N-[(1S)-1-phenylethyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



●2 HCl


RN 344464-69-3 CAPLUS
 CN 1,2-Ethanediamine, N-[5-{2-[(1S)-1-phenylethyl]amino}-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl-, trihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●3 HCl


RN 344464-71-7 CAPLUS
 CN 2-Pyridazinamine, 4-[6-(4-amino-1-piperidinyl)-3-(trifluoromethyl)phenyl]-4-pyrimidinyl-N-[(1S)-1-phenylethyl]-, trihydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
Absolute stereochemistry.

●3 HCl

RN 344464-72-8 CAPLUS
 CN 2-Pyridazinamine, N-[(1S)-1-phenylethyl]-4-[6-phenyl-3-(trifluoromethyl)phenyl]-4-pyridazinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 344464-74-0 CAPLUS
 CN 2-Pyridazinamine, N-[(1S)-1-phenylethyl]-4-[6-(phenylsulfinyl)-3-(trifluoromethyl)phenyl]-4-pyridazinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 344464-75-1 CAPLUS
 CN 3-Pyridazinamine, N-(3-methoxypropyl)-5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 344464-76-2 CAPLUS
 CN 3-Pyridazinamine, N-(3-ethoxypropyl)-5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN


(Continued)



RN 344464-77-3 CAPLUS

CN 3-Pyridazinamine, N-[3-(1H-imidazol-1-yl)propyl]-5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 344464-78-4 CAPLUS

CN 3-Pyridazinamine, 5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-N-[1-(phenylmethyl)-4-piperidinyl]-6-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 344464-79-5 CAPLUS

CN Carbamic acid, [2-[(5-[(1S)-1-phenylethyl]amino)-4-pyrimidinyl]-6-(3-(trifluoromethyl)phenyl)-3-pyridazinyl]amino]ethyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 344464-80-8 CAPLUS

CN 3-Pyridazinamine, N-[(3,4-dimethoxyphenyl)methyl]-5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 344464-81-9 CAPLUS

CN 2-Pyridimidamine, 4-[6-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 344464-83-1 CAPLUS

CN 2-Pyridimidamine, 4-[6-(4-methyl-1-piperazinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 344464-82-0 CAPLUS

CN 2-Pyridimidamine, 4-[6-(1H-imidazol-1-yl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 344464-84-2 CAPLUS


CN 2-Pyridimidamine, N-[(1S)-1-phenylethyl]-4-[6-(1-piperazinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 344464-85-3 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-(3,4-dihydro-2(1H)-isoquinolinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 344464-86-4 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-(3,5-dimethyl-1-piperidinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 344464-87-5 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-[1,4'-bipiperidin]-1'-yl-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 344464-88-6 CAPLUS
 CN 3-Pyridazinamine, N-methyl-N-(1-methyl-3-pyrrolidinyl)-5-[2-[(1S)-1-phenylethyl]amino]-4-pyridazinyl]-6-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 344464-89-7 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 344464-90-0 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-(4-(4-fluorophenyl)-1-piperazinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 344464-91-1 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-(4-methyl-1-piperidinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 344464-92-2 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-(3-methyl-1-piperidinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 344464-93-3 CAPLUS
CN 1,2-Ethanediamine, N,N,N'-trimethyl-N'-(5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl)-6-(3-(trifluoromethyl)phenyl)-3-pyridazinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 344464-94-4 CAPLUS
CN 2-Pyrimidinamine, N-[(1S)-1-phenylethyl]-4-[6-(4-phenyl-1-piperazinyl)-3-(3-(trifluoromethyl)phenyl)-4-pyridazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 344464-95-5 CAPLUS
CN 2-Pyrimidinamine, 4-[6-(octahydro-1(2H)-quinolinyl)-3-(3-(trifluoromethyl)phenyl)-4-pyridazinyl]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 344464-96-6 CAPLUS
CN 2-Pyrimidinamine, N-[(1S)-1-phenylethyl]-4-[6-(1-piperidinyl)-3-(3-(trifluoromethyl)phenyl)-4-pyridazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 344464-97-7 CAPLUS
CN 3-Pyridazinamine, N,N-bis(2-methoxyethyl)-5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl-6-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 344464-98-8 CAPLUS
CN 3-Pyridazinamine, N-(cyclopropylmethyl)-5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl-N-propyl-6-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 344464-99-9 CAPLUS
CN 2-Pyrimidinamine, 4-[6-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]-3-(3-(trifluoromethyl)phenyl)-4-pyridazinyl]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 344465-00-5 CAPLUS
CN 2-Pyrimidinamine, 4-[6-(2,6-dimethyl-4-morpholinyl)-3-(3-(trifluoromethyl)phenyl)-4-pyridazinyl]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN


(Continued)



RN 344465-01-6 CAPLUS

CN 2-Pyrimidinamine, N-[(1S)-1-phenylethyl]-4-[6-(4-thiomorpholinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 344465-02-7 CAPLUS

CN 2-Pyrimidinamine, N-[(1S)-1-phenylethyl]-4-[6-(4-phenyl-1-piperidinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN


(Continued)



RN 344465-03-8 CAPLUS

CN 3-Pyridazinamine, N-ethyl-5-[2-[(1S)-1-phenylethyl]amino]-4-pyridinyl-N-(phenylmethyl)-6-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 344465-04-9 CAPLUS

CN 3-Pyridazinamine, N,N-dibutyl-5-[2-[(1S)-1-phenylethyl]amino]-4-pyridinyl-6-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN


(Continued)



RN 344465-05-0 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(4-(3,4-dimethylphenyl)-1-piperazinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 344465-06-1 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(3-methyl-4-phenyl-1-piperazinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN


(Continued)



RN 344465-07-2 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(4-methoxyphenyl)-3-methyl-1-piperazinyl]-3-[3-(trifluoromethyl)phenyl]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 344465-08-3 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(hexahydro-1H-azepin-1-yl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 344465-09-4 CAPLUS
 CN 3-Pyridazinamine, N-methyl-5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl-N-2-propynyl-6-[3-(trifluoromethyl)phenyl] - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 344465-10-7 CAPLUS
 CN 3-Piperidinecarboxylic acid, 1-[5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 344465-11-8 CAPLUS
 CN 3-Pyridazinamine, N-methyl-N-(1-methyl-4-piperidinyl)-5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl-6-[3-(trifluoromethyl)phenyl] - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 344465-12-9 CAPLUS
 CN 2-Pyridazinamine, 4-[6-(2-methyl-1-piperidinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl] - (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 344465-13-0 CAPLUS
 CN 3-Pyridazinamine, N-(2-phenylethyl)-5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl-N-(phenylmethyl)-6-[3-(trifluoromethyl)phenyl] - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 344465-14-1 CAPLUS
 CN 3-Pyridazinamine, N-methyl-5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl-N-[2-(2-pyridinyl)ethyl]-6-[3-(trifluoromethyl)phenyl] - (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 344465-15-2 CAPLUS
 CN 3-Piperidinecarboxamide, N,N-diethyl-1-[5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 344465-16-3 CAPLUS
 CN 3-Piperidinecarboxamide, 1-[5-(2-[(1S)-1-phenylethyl]amino)-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl - (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 344465-17-4 CAPLUS
 CN 4-Piperidinonecarboxamide, 1-[5-{2-[(1S)-1-phenylethyl]amino}-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 344465-18-5 CAPLUS
 CN 1H-Indole-3-ethanamine, N-methyl-N-[5-{2-[(1S)-1-phenylethyl]amino}-4-


L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 (CA INDEX NAME)

Absolute stereochemistry.



RN 344465-19-6 CAPLUS
 CN 4-Piperidinol, 4-phenyl-1-[5-{2-[(1S)-1-phenylethyl]amino}-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 344465-20-9 CAPLUS
 CN 4-Piperidinol, 4-(4-chlorophenyl)-1-[5-{2-[(1S)-1-phenylethyl]amino}-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 344465-21-0 CAPLUS
 CN 4-Piperidinol, 4-(4-bromophenyl)-1-[5-{2-[(1S)-1-phenylethyl]amino}-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 344465-22-1 CAPLUS
 CN 3-Pyridazinamine, N-(2-methoxymethyl)-5-{2-[(1S)-1-phenylethyl]amino}-4-pyrimidinyl-N-propyl-6-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 344465-23-2 CAPLUS
 CN 3-Pyridazinamine, N-ethyl-N-(2-methoxymethyl)-5-{2-[(1S)-1-phenylethyl]amino}-4-pyrimidinyl-6-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 344465-24-3 CAPLUS
 CN 3-Pyridazinamine, N-(2-methoxymethyl)-N-methyl-5-{2-[(1S)-1-phenylethyl]amino}-4-pyrimidinyl-6-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 344465-25-4 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-(2-methyl-1H-imidazol-1-yl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 344465-26-5 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-(4-methyl-2-phenyl-1H-imidazol-1-yl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 344465-27-6 CAPLUS
 CN 2-Pyrimidinamine, N-[(1S)-1-phenylethyl]-4-[6-(2-phenyl-1H-imidazol-1-yl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 344465-28-7 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-(4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 344465-29-8 CAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 344465-31-2 CAPLUS
 CN 1,2-Ethanediamine, N-ethyl-N',N'-dimethyl-N-[5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 344465-33-4 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-(4-(2,5-dimethylphenyl)-1-piperazinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 344465-34-5 CAPLUS
 CN Carbamic acid, [2-[5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]amino]ethyl-, 1,1-dimethylethyl ester, dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 2 HCl

RN 344465-35-6 CAPLUS
 CN 3-Pyridinamine, N-[(3,4-dimethoxyphenyl)methyl]-5-[2-[(1S)-1-phenylethyl]amino]-4-pyridazinyl-6-[3-(trifluoromethyl)phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 2 HCl

RN 344465-36-7 CAPLUS
 CN 2-Pyridinamine, 4-[6-(4-methyl-1-piperazinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]-, trihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 3 HCl

RN 344465-37-8 CAPLUS
 CN 2-Pyridinamine, N-[(1S)-1-phenylethyl]-4-[6-(1-piperazinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-, trihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 3 HCl

RN 344465-38-9 CAPLUS
 CN 2-Pyridinamine, 4-[6-(3,4-dihydro-2H-isochinolinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1
 CRN 344464-85-3
 CMF C32 H27 F3 N6

Absolute stereochemistry.




CM 2
 CRN 76-05-1
 CMF C2 H F3 O2



RN 344465-40-3 CAPLUS
 CN 2-Pyridinamine, 4-[6-(3,5-dimethyl-1-piperidinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1
 CRN 344464-86-4
 CMF C30 H31 F3 N6

Absolute stereochemistry.




CM 2
 CRN 76-05-1
 CMF C2 H F3 O2



RN 344465-42-5 CAPLUS
 CN 2-Pyridinamine, 4-[6-[1,4'-bipiperidin]-1'-yl-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1
 CRN 344464-87-5
 CMF C33 H36 F3 N7

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2


RN 344465-44-7 CAPLUS

CN 3-Pyridazinamine, N-methyl-N-(1-methyl-3-pyrrolidinyl)-5-{2-[(1S)-1-phenylethyl]amino}-4-pyridazinyl-6-[3-(trifluoromethyl)phenyl]-, tris(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 344464-88-6
CMF C29 H30 F3 N7

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2


RN 344465-46-9 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]-, tris(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 344464-89-7
CMF C29 H30 F3 N7

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2


RN 344465-48-1 CAPLUS

CN 2-Pyrimidinamine, 4-[6-[4-(4-fluorophenyl)-1-piperazinyl]-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]-, tris(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 344464-90-0
CMF C33 H29 F4 N7

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2


RN 344465-50-5 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(4-methyl-1-piperidinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 344464-91-1
CMF C29 H29 F3 N6

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 344465-52-7 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-(3-methyl-1-piperidinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 344464-92-2
CMF C29 H29 F3 N6

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2


RN 344465-53-8 CAPLUS

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 1,2-Ethanediamine, N,N,N'-trimethyl-N-[5-{2-[(1S)-1-phenylethyl]amino}-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl-, tris(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 344464-93-3
CMF C28 H30 F3 N7

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2


RN 344465-54-9 CAPLUS
 CN 2-Pyrimidinamine, N-[(1S)-1-phenylethyl]-4-[6-(4-phenyl-1-piperazinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl-, tris(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 344464-94-4
CMF C33 H30 F3 N7

Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2

CRN 76-05-1
CMF C2 H F3 O2


RN 344465-55-0 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-(octahydro-1(2H)-quinolinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 344464-95-5
CMF C32 H33 F3 N6

Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2


CRN 76-05-1
CMF C2 H F3 O2

RN 344465-56-1 CAPLUS
 CN 2-Pyrimidinamine, N-[(1S)-1-phenylethyl]-4-[6-(1-piperidinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN

(Continued)




RN 344465-57-2 CAPLUS
 CN 3-Pyridazinamine, N,N-bis(2-methoxyethyl)-5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl-6-(3-(trifluoromethyl)phenyl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 344464-97-7
CMF C29 H31 F3 N6 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 344465-59-3 CAPLUS
 CN 3-Pyridazinamine, N-(cyclopropylmethyl)-5-{2-[(1S)-1-phenylethyl]amino}-4-pyrimidinyl-6-(3-(trifluoromethyl)phenyl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 344464-98-8
CMF C30 H31 F3 N6

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2


RN 344465-59-4 CAPLUS
 CN 2-Pyridazinamine, 4-[6-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl-6-(1S)-1-phenylethyl-, tris(trifluoroacetate) (9CI) (CA INDEX NAME)

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CM 1

CRN 344464-99-9
CMF C40 H35 Cl F3 N7

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2


RN 344465-60-7 CAPLUS
 CN 2-Pyridazinamine, 4-{6-(2,6-dimethyl-4-morpholinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl}-N-[(1S)-1-phenylethyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 344465-00-5
CMF C29 H29 F3 N6 O

Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2


CRN 76-05-1
CMF C2 H F3 O2

RN 344465-61-8 CAPLUS
 CN 2-Pyridazinamine, N-[(1S)-1-phenylethyl]-4-{6-(4-thiomorpholinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl}-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 344465-01-6
CMF C27 H25 F3 N6 S

Absolute stereochemistry.



CH 2


CRN 76-05-1
CHF C2 H F3 O2

RN 344465-62-9 CAPLUS
 CN 2-Pyrimidinamine, N-[{(1S)-1-phenylethyl}-4-[6-(4-phenoxy-1-piperidinyl)-3-(3-(trifluoromethyl)phenyl)-4-pyridazinyl]-, bis(trifluoroacetate) (9CI)
 (CA INDEX NAME)

CH 1

CRN 344465-02-7
CHF C34 H31 F3 N6

Absolute stereochemistry.



CH 2


CRN 76-05-1
CHF C2 H F3 O2

RN 344465-63-0 CAPLUS
 CN 3-Pyridazinamine, N-ethyl-5-[2-[(1S)-1-phenylethyl]amino]-4-pyridazinyl-
 N-(phenylmethyl)-6-[3-(trifluoromethyl)phenyl]-, bis(trifluoroacetate)
 (9CI) (CA INDEX NAME)

CH 1

CRN 344465-03-8
CHF C32 H29 F3 N6

Absolute stereochemistry.



CH 2


CRN 76-05-1
CHF C2 H F3 O2

RN 344465-64-1 CAPLUS
 CN 3-Pyridazinamine, N,N-dibutyl-5-[2-[(1S)-1-phenylethyl]amino]-4-
 pyridazinyl-6-[3-(trifluoromethyl)phenyl]-, bis(trifluoroacetate) (9CI)
 (CA INDEX NAME)

CH 1

CRN 344465-04-9
CHF C31 H35 F3 N6

Absolute stereochemistry.



CH 2

CRN 76-05-1
CHF C2 H F3 O2

RN 344465-65-2 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-[4-(3,4-dimethylphenyl)-1-piperazinyl]-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]-, triis(trifluoroacetate) (9CI) (CA INDEX NAME)


CH 1

CRN 344465-05-0
CHF C35 H34 F3 N7

Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN

(Continued)



CM 2


CRN 76-05-1
CMB C2 H F3 O2RN 344465-66-3 CAPLUS
CN 2-Pyrimidinamine, 4-[6-(3-methyl-4-phenyl-1-piperazinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]-, tris(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 344465-06-1
CMB C34 H32 F3 N7

Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2


CRN 76-05-1
CMB C2 H F3 O2RN 344465-67-4 CAPLUS
CN 2-Pyrimidinamine, 4-[6-[4-(4-methoxyphenyl)-3-methyl-1-piperazinyl]-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]-, tris(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 344465-07-2
CMB C35 H34 F3 N7 O

Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2


CRN 76-05-1
CMB C2 H F3 O2RN 344465-68-5 CAPLUS
CN 2-Pyrimidinamine, 4-[6-(hexahydro-1H-azepin-1-yl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 344465-08-3
CMB C29 H29 F3 N6

Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




CM 2

CRN 76-05-1
CMB C2 H F3 O2RN 344465-69-6 CAPLUS
CN 3-Pyridazinamine, N-methyl-5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl-, N-2-propynyl-6-[3-(trifluoromethyl)phenyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 344465-09-4
CMB C27 H23 F3 N6

Absolute stereochemistry.



CH 2

CRN 76-05-1
CNF C2 H F3 O2


RN 344465-70-9 CAPLUS

CN 3-Pyridinecarboxylic acid, 1-[5-{2-[(1S)-1-phenylethyl]amino}-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl-, ethyl ester, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 344465-10-7
CNF C31 H31 F3 N6 O2

Absolute stereochemistry.



CH 2

CRN 76-05-1
CNF C2 H F3 O2


RN 344465-71-0 CAPLUS

CN 3-Pyridazinamine, N-methyl-N-(1-methyl-4-piperidinyl)-5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-, tris(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 344465-11-8
CNF C30 H32 F3 N7

Absolute stereochemistry.




CH 2

CRN 76-05-1
CNF C2 H F3 O2RN 344465-72-1 CAPLUS
CN 2-Pyridinamine, 4-[6-(2-methyl-1-piperidinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 344465-12-9
CNF C29 H29 F3 N6

Absolute stereochemistry.



CH 2

CRN 76-05-1
CNF C2 H F3 O2RN 344465-73-2 CAPLUS
CN 3-Pyridazinamine, N-(2-phenylethyl)-5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl-N-(phenylmethyl)-6-[3-(trifluoromethyl)phenyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)


CH 1

CRN 344465-13-0
CNF C38 H33 F3 N6

Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN

(Continued)



CH 2

CRN 76-05-1
CMF C2 H F3 O2


RN 344465-74-3 CAPLUS
CN 3-Pyridazinamine, N-methyl-5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl-,
N-[2-(2-pyridinyl)ethyl]-6-[3-(trifluoromethyl)phenyl]-,
bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 344465-14-1
CMF C31 H28 F3 N7

Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CH 2

CRN 76-05-1
CMF C2 H F3 O2


RN 344465-75-4 CAPLUS
CN 3-Piperidinecarboxamide, N,N-diethyl-1-[5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl-,
bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 344465-15-2
CMF C33 H36 F3 N7 O

Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CH 2

CRN 76-05-1
CMF C2 H F3 O2


RN 344465-76-5 CAPLUS
CN 3-Piperidinecarboxamide, 1-[5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl-,
bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 344465-16-3
CMF C29 H28 F3 N7 O

Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CH 2

CRN 76-05-1
CMF C2 H F3 O2

RN 344465-77-6 CAPLUS
CN 4-Piperidinecarboxamide, 1-[5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl-,
bis(trifluoroacetate) (9CI) (CA INDEX NAME)


CH 1

CRN 344465-17-4
CMF C29 H28 F3 N7 O

Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN

(Continued)



CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 344465-78-7 CAPLUS
CN 1H-Indole-3-ethanamine, N-methyl-N-[5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1
CRN 344465-18-5
CMF C34 H30 F3 N6 O

Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 344465-79-8 CAPLUS
CN 4-Piperidinol, 4-phenyl-1-[5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1
CRN 344465-19-6
CMF C34 H31 F3 N6 O

Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 344465-80-1 CAPLUS
CN 4-Piperidinol, 4-(4-chlorophenyl)-1-[5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1
CRN 344465-20-9
CMF C34 H30 Cl F3 N6 O

Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




CM 2
CRN 76-05-1
CMF C2 H F3 O2



RN 344465-81-2 CAPLUS
CN 4-Piperidinol, 4-(4-bromophenyl)-1-[5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1
CRN 344465-21-0
CMF C34 H30 Br F3 N6 O

Absolute stereochemistry.



CM 2

CRN 76-05-1
CHF C2 H F3 O2


RN 344465-82-3 CAPLUS

CN 3-Pyridazinamine, N-(2-methoxymethyl)-5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl-N-propyl-6-[3-(trifluoromethyl)phenyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 344465-22-1
CHF C29 H31 F3 N6 O

Absolute stereochemistry.



CM 2

CRN 76-05-1
CHF C2 H F3 O2


RN 344465-83-4 CAPLUS

CN 3-Pyridazinamine, N-ethyl-N-(2-methoxymethyl)-5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl-6-[3-(trifluoromethyl)phenyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 344465-23-2
CHF C28 H29 F3 N6 O

Absolute stereochemistry.



CM 2

CRN 76-05-1
CHF C2 H F3 O2


RN 344465-84-5 CAPLUS

CN 3-Pyridazinamine, N-(2-methoxymethyl)-N-methyl-5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl-6-[3-(trifluoromethyl)phenyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 344465-24-3
CHF C27 H27 F3 N6 O

Absolute stereochemistry.



CM 2

CRN 76-05-1
CHF C2 H F3 O2

RN 344465-85-6 CAPLUS

CN 2-Pyridazinamine, 4-[6-(2-methyl-1H-imidazol-1-yl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 344465-25-4
CHF C27 H22 F3 N7

Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPIUS COPYRIGHT 2006 ACS on STN

(Continued)



CH 2

CRN 76-05-1
CMF C2 H F3 O2


RN 344465-86-7 CAPIUS
 CN 2-Pyrimidinamine, 4-[6-(4-methyl-2-phenyl-1H-imidazol-1-yl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 344465-26-5
CMF C33 H26 F3 N7

Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPIUS COPYRIGHT 2006 ACS on STN (Continued)



CH 2

CRN 76-05-1
CMF C2 H F3 O2


RN 344465-87-8 CAPIUS
 CN 2-Pyrimidinamine, N-[(1S)-1-phenylethyl]-4-[6-(2-phenyl-1H-imidazol-1-yl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 344465-27-6
CMF C32 H24 F3 N7

Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPIUS COPYRIGHT 2006 ACS on STN (Continued)



CH 2

CRN 76-05-1
CMF C2 H F3 O2


RN 344465-88-9 CAPIUS
 CN 2-Pyrimidinamine, 4-[6-{4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl}-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]-, tris(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 344465-28-7
CMF C35 H32 F3 N7 O2

Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPIUS COPYRIGHT 2006 ACS on STN (Continued)



CH 2


CRN 76-05-1
CMF C2 H F3 O2

RN 344465-89-0 CAPIUS
 CN 1-Piperazinecarboxylic acid, 4-[5-{2-[(1S)-1-phenylethyl]amino}-4-pyrimidinyl]-6-(3-(trifluoromethyl)phenyl)-3-pyridazinyl-, ethyl ester, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 344465-29-8
CMF C30 H30 F3 N7 O2

Absolute stereochemistry.



CH 2


CRN 76-05-1
CNF C2 H F3 O2

RN 344465-90-3 CAPLUS
CN 1,2-Ethanediamine, N-ethyl-N'-dimethyl-N-[5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl-, triis(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 344465-31-2
CNF C29 H32 F3 N7

Absolute stereochemistry.



CH 2


CRN 76-05-1
CNF C2 H F3 O2

RN 344465-91-4 CAPLUS
CN 2-Pyrimidinamine, 4-[6-(4-(2,5-dimethylphenyl)-1-piperazinyl)-3-(3-(trifluoromethyl)phenyl)-4-pyridazinyl]-N-[(1S)-1-phenylethyl]-, triis(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 344465-33-4
CNF C35 H34 F3 N7

Absolute stereochemistry.




CH 2

CRN 76-05-1
CNF C2 H F3 O2


IT 344465-97-0P 344465-98-1P 344465-99-2P
344466-00-0P 344466-01-9P 344466-02-0P
344466-03-1P 344466-04-2P 344466-05-3P
344466-06-4P 344466-07-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyridazine derivs. as inhibitors of cytokine formation
and activity for the treatment of cytokine-mediated diseases such as
arthritis)
RN 344465-97-0 CAPLUS
CN 3(2H)-Pyridazinone, 5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 344465-98-1 CAPLUS
CN 2-Pyrimidinamine, 4-[6-chloro-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 344465-99-2 CAPLUS
CN 3(2H)-Pyridazinone, 5-[2-(methylthio)-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 344466-00-8 CAPLUS
CN Pyridazine, 6-chloro-4-[2-(methylthio)-4-pyrimidinyl]-3-[3-

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN
(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


(Continued)



RN 344466-01-9 CAPLUS
CN 3-Pyridazinamine, N,N-dimethyl-5-[2-(methylthio)-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 344466-02-0 CAPLUS
CN 3-Pyridazinamine, N,N-dimethyl-5-[2-(methylsulfonyl)-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 344466-03-1 CAPLUS
CN Methanesulfonic acid, trifluoro-, 5-[2-(methylthio)-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 344466-04-2 CAPLUS
CN Morpholine, 4-[5-[2-(methylthio)-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 344466-05-3 CAPLUS
CN Morpholine, 4-[5-[2-(methylsulfonyl)-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 344466-06-4 CAPLUS
CN Pyridazine, 4-[2-(methylthio)-4-pyrimidinyl]-6-phenyl-3-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 344466-07-5 CAPLUS
CN Pyridazine, 4-[2-(methylsulfonyl)-4-pyrimidinyl]-6-phenyl-3-(3-(trifluoromethyl)phenyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 13 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2000-368342 CAPLUS

DOCUMENT NUMBER: 133:4673

TITLE: Preparation of azines as cytokine inhibitors

INVENTOR(S): Claremon, David A.; Ponticello, Gerald S.

PATENT ASSIGNEE(S): Merck & Co., Inc., USA

SOURCE: PCT Int. Appl., 72 pp.


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
WO 2000031065	A1	20000602	WO 1999-US27184	19991116	
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KS, LS, MW, SD, SL, SZ, T2, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CN, GA, GN, GW, ML, MR, NE, SN, TD, TG	B1	20020226	US 1999-433247	19991104	
US 6350744	AA	20000602	CA 1999-2350969	19991116	
CA 2350969	A1	20010912	EP 1999-960406	19991116	
EP 1131314	R: AT, BE, CH, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO	T2	20020917	JP 2000-583893	19991116
JP 2002530399	T2	20020917	AU 2000-17297	19991116	
AU 756862	B2	20030123	US 1998-109306P	P 19981120	
PRIORITY APPLN. INFO.:			WO 1999-US27184	V 19991116	
OTHER SOURCE(S):	MARPAT 133:4673				



AB Title compds. [I; A = H, (N-alkylated) pyrrolidinyl, morpholinyl, piperidinyl; Q, U, V, W = CH, N; R1 = H, aralkylamino; R2-R4 = H, halo, OH, CF3, amino, NO2, (substituted) alkyl, alkoxy, cycloalkyl, acyl], were prepared as cytokine inhibitors (no data). Thus, title compound (II) was prepared in several steps via a-(2-methylthiopyrimidin-4-yl)-3-

L4 ANSWER 13 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 trifluoromethylacetophenone.
 IT 271247-18-8P 271247-19-9P 271247-20-2P
 271247-21-3P 271247-22-4P 271247-23-5P
 271247-37-1P 271247-38-2P 271247-41-7P
 271247-44-0P
 RL: BAE (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of azines as cytokine inhibitors)
 RN 271247-18-8 CAPLUS
 CN 2-Pyrimidinamine, N-[(1S)-1-phenylethyl]-4-[6-(4-piperidinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 271247-19-9 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-(1-methyl-4-piperidinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 13 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 271247-20-2 CAPLUS
 CN 2-Pyridazine, 6-(1-methyl-4-piperidinyl)-4-(4-pyridinyl)-3-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 271247-21-3 CAPLUS
 CN 2-Pyridazine, 6-(4-piperidinyl)-4-(4-pyridinyl)-3-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 13 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 271247-22-4 CAPLUS
 CN 2-Pyridinamine, N-[(1S)-1-phenylethyl]-4-[6-(4-piperidinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 271247-23-5 CAPLUS
 CN 2-Pyridinamine, 4-[6-(1-methyl-4-piperidinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 13 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 (trifluoromethyl)phenyl]-4-pyridazinyl]- dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 271247-38-2 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-(1-methyl-4-piperidinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]- monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 271247-41-7 CAPLUS
 CN Pyridazine, 6-(4-piperidinyl)-4-(4-pyridinyl)-3-[3-(trifluoromethyl)phenyl]-, trihydrochloride (9CI) (CA INDEX NAME)

RN 271247-37-1 CAPLUS
 CN 2-Pyrimidinamine, N-[(1S)-1-phenylethyl]-4-[6-(4-piperidinyl)-3-[3-

Habte


09/11/2006



●3 HCl

RN 271247-44-0 CAPLUS
CN 2-Pyridinamine, 4-[6-(1-methyl-4-piperidinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]-, dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●2 HCl


IT 271247-34-8P 271247-35-9P 271247-36-0P
271247-40-6P 271247-42-8P 271247-43-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of azines as cytokine inhibitors)

RN 271247-34-8 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[5-[2-(methylthio)-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



Intermediate


RN 271247-35-9 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[5-[2-(methylsulfonyl)-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




Intermediate

RN 271247-36-0 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 271247-40-6 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[5-(4-pyridinyl)-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 271247-42-8 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[5-(2-fluoro-4-pyridinyl)-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 271247-43-9 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[5-[2-[(1S)-1-phenylethyl]amino]-4-pyridinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT:

2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 14 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1999:421654 CAPLUS
DOCUMENT NUMBER: 131:58754
TITLE: Preparation of substituted pyridine and pyridazine compounds as TNF- α and IL-1 inhibitors
INVENTOR(S): Amgen, Nathan B.; Hwang, Chan Kou; Spohr, Ulrike D.
PATENT ASSIGNEE(S): Amgen Inc., USA
SOURCE: PCT Int. Appl., 188 pp.
CODEN: PIXKD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9932448	A1	19990701	WO 1998-US27298	19981221
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, JP, KE, KG, KP, KR, KZ, LC, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UW, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GV, ML, MR, NE, SN, TD, TG				
US 6174901	B1	20010116	US 1998-215426	19981218
CA 2315827	AA	19990701	CA 1998-2315827	19981221
AU 9920911	A1	19990712	AU 1999-20911	19981221
AU 755421	B2	20021212		
EP 1042293	A1	20001011	EP 1998-965447	19981221
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2001526263	T2	20011218	JP 2000-525385	19981221
PRIORITY APPLN. INFO.:			US 1997-681999	P 19971219
			US 1998-215426	A 19981218
			WO 1998-US27298	W 19981221
OTHER SOURCE(S):	MARPAT 131:59754			
GI:				



AB Title compds. (e.g., I; R = (S)-NHCH₂CH(NH₂)CH₂Ph; R1 = 4-pyridyl) (II; R2 = substituted Ph) were prepared for use in lowering TNF- α and IL-1


L4 ANSWER 14 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
NAME)




REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RR FORMAT.

L4	ANSWER 14 OF 30 CAPLUS COPYRIGHT 2006 ACS ON STN	(Continued)
	blood levels. Thus, cyclopentenone oxime III, prep'd. in 6 steps from 4-pyridinemethanol and MeCH ₂ CHO, underwent Beckmann rearrangement and the dehydrated and chlorinated product (generated by (S)-H2NCH2CH(NH2)CH2Ph to give II (R = CGH4Me-3). Data for bio. activity of I were given.	
IT	228392-74-3P	
	RL: BAC (Biological activity or effectors, except adverse); BSU (Biological study, unclassified); SPU (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses); (preparation of substituted pyridin- and pyridazine compds. as TNF- α and IL-1 inhibitors)	
RN	228392-74-3 CAPLUS	
CN	1,2-Propanediamine, N1-[6-(4-fluorophenyl)-5-(4-pyridinyl)-3-pyridazinyl]-3-phenyl-, (2S)- (9CI) (CA INDEX NAME)	

Absolute stereochemistry



IT 228392-98-1P 228392-99-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of substituted pyridine and pyridazine compds. as TNF- α
and IL-1 inhibitors)
RN 228392-98-1 CAPLUS
CN 3(ZH)-Fryridin-6-yl-6-(4-fluorophenyl)-5-(4-pyridinyl)- (9CI) (CA INDEX
NAME)



RN 228392-99-2 CAPLUS
CN Pyridazine, 6-chloro-3-(4-fluorophenyl)-4-(4-pyridinyl)- (9CI) (CA INDEX)

L4 ANSWER 14 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
NAME)


14 ANSWER 15 OF 30 CAPIUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1999:350658 CAPIUS
DOCUMENT NUMBER: 13115263
TITLE: Preparation of pyridazine derivatives as
interleukin-1 β production inhibitors
INVENTOR(S): Ohuchi, Masao; Ryotan, Yoshihori; Shigyo, Hiromichi;
Koshi, Tomoyuki; Kitamura, Takahiro; Ohgiya, Tadaaki;
Matsuda, Takayuki; Yamazaki, Yukiochi; Kumai,
Natsumi; Kotaka, Kyoko; Yoshizaki, Hideo; Habata,
Yuriko
PATENT ASSIGNEE(S): Kowa Co., Ltd., Japan
SOURCE: PCT Int. Appl., 147 pp.
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9925697	A1	19990527	WO 1998-JP5023	19991102
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, DE, DK, ES, FI, GB, GD, GE, GH, GM, HU, ID, IL, IS, KE, KG, KW, LA, LC, LU, LS, LT, LV, MD, MG, MK, MN, MW, NU, NZ, PL, PT, RO, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, US, VN, ZW			
RW:	CH, GH, KE, LS, MW, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GR, IE, IT, LU, MC, NL, PT, SE, BE, BJ, CG, CI, GN, GU, MR, NE, SN, TD, TO			
JP 11152274	A2	19980608	JP 1997-318133	19971116
CA 2307111	AA	19980527	CA 1998-2307111	19981109
AU 9897626	A1	19980607	AU 1998-97626	19981109
AU 738595	B2	20000920		
BR 9813998	A	20000926	BR 1998-13998	19981109
EP 1043317	A1	20001011	EP 1998-951732	19981109
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
NZ 504045	A	20010629	NZ 1998-504045	19981110
RU 2209813	C2	20030810	RU 2000-115577	19981110
JP 2000198776	A2	20000718	JP 1998-319281	19981110
JP 3335132	B2	20021015		
TW 502025	B	20020911	TW 1998-87119032	19981117
NO 2000002169	A	20000518	NO 2000-2169	20000427
NO 316021	B1	20031201		
US 6348468	B1	20020219	US 2000-530949	20000515
HK 1032969	A1	20040820	HK 2001-103597	20010524
US 2002123496	A1	20020905	US 2001-996804	20011130
US 2004147516	A1	20040729	US 2004-757525	20040115
US 2005065155	A1	20050324	US 2004-986350	20041115
US 2005267113	A1	20051201	US 2005-203174	20050915
US 2006160804	A1	20060720	US 2006-385932	20060322
PRIORITY APPN. INFO.:				
		JP 1997-318132	A 19971119	
		JP 1997-318133	A 19971119	
		JP 1998-311880	A 19981102	
		WO 1998-JP5023	V 19981109	
		US 2000-530949	A3 20000515	
		'S 2001-996804	BI 20011130	
		US 2004-757525	BI 20040115	
		US 2004-986350	BI 20041115	

Habte

09/11/2006

L4 ANSWER 15 OF 30 CAPIUS COPYRIGHT 2006 ACS on STN (Continued)
 OTHER SOURCE(S): MARPAT 131:5263




AB The title compds. I [R1 is (substituted) aryl; R2 is Ph substituted with lower alkoxyl, lower alkylthio or the like at the position 4; R3 is H, lower alkoxyl, lower haloalkyl, lower cycloalkyl, (substituted) aryl, (substituted) aryl oxy, (substituted) nitrocarbonyl residue, (substituted) aminocarbonyl or lower alkylcarbonyl; A is a single bond, lower alkylene or lower alkenylene; X is O or S and the broken line between the carbon atoms at the positions 4 and 5 represents a single or double bond] are prepared. These compds. exhibit excellent inhibitory activity against the production of interleukin-1 β , thus being useful as preventive and therapeutic drugs for immunol. diseases, inflammatory diseases, ischemic diseases and so on. In an *in vitro* test for inhibition of interleukin-1 β production, 5,6-bis(4-methoxyphenyl)-2-(4-chlorocinnamyl)-2H-pyridazin-3-one showed IC50 of 0.1 μ M.

IT 225666-37-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of pyridazine derivs. as interleukin-1 β production inhibitors)

RN 225666-37-5 CAPIUS

CN 3(2H)-Pyridazinone, 6-(4-methoxyphenyl)-5-(4-pyridinyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 16 OF 30 CAPIUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1999-51061 CAPIUS
 DOCUMENT NUMBER: 130-209659
 TITLE: Pyridazinones. XV. Synthesis of 6-aryl-5-amino-3(2H)-pyridazinones as potential platelet aggregation inhibitors

AUTHOR(S): Estevez, Isabel; Ravina, Enrique; Sotelo, Eddy
 CORPORATE SOURCE: Department of Organic Chemistry, Laboratory of Medicinal Chemistry, Faculty of Pharmacy, University of Santiago de Compostela, Santiago de Compostela, 15706, Spain
 SOURCE: Journal of Heterocyclic Chemistry (1998), 35(6), 1421-1428

PUBLISHER: HeteroCorporation
 DOCUMENT TYPE: Journal
 LANGUAGE: English


AB Several 3(2H)-pyridazinones with amino groups at C-5 of the pyridazine nucleus have been prepared. The 6-aryl-5-halo-3(2H)-pyridazinones obtained from mucochloride and mucobromic acid lead to the corresponding 5-alkylamino-3(2H)-pyridazinones, which were tested as platelet aggregation inhibitors.

IT 15904-59-2 220967-35-1P 220967-36-2P
 220967-37-3P 220967-38-4P 220967-39-5P
 220967-41-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PNK (Preparation)
 (preparation of aryl(amino)pyridazinones with potential platelet aggregation inhibiting activity from amination of aryl(halo)pyridazinones)

RN 15904-59-2 CAPIUS


CN 3(2H)-Pyridazinone, 6-(4-methoxyphenyl)-5-(1-piperidinyl)- (9CI) (CA INDEX NAME)



RN 220967-35-1 CAPIUS


CN 3(2H)-Pyridazinone, 6-phenyl-5-(1-piperidinyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 16 OF 30 CAPIUS COPYRIGHT 2006 ACS on STN (Continued)




RN 220967-36-2 CAPIUS

CN 3(2H)-Pyridazinone, 6-(3,4-dimethoxyphenyl)-5-(1-piperidinyl)- (9CI) (CA INDEX NAME)



RN 220967-37-3 CAPIUS


CN 3(2H)-Pyridazinone, 6-(4-methoxyphenyl)-5-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 220967-38-4 CAPIUS


CN 3(2H)-Pyridazinone, 6-(3,4-dimethoxyphenyl)-5-(1-piperazinyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 16 OF 30 CAPIUS COPYRIGHT 2006 ACS on STN (Continued)




RN 220967-39-5 CAPIUS

CN 3(2H)-Pyridazinone, 6-(4-methoxyphenyl)-5-(4-phenyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 220967-41-9 CAPIUS

CN 3(2H)-Pyridazinone, 6-(4-methoxyphenyl)-5-[4-(2-methoxyphenyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)




IT 132814-16-5P 220967-40-8P 220967-42-0P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of aryl(amino)pyridazinones with potential platelet aggregation)


RN 132814-16-5 CAPIUS

CN 3(2H)-Pyridazinone, 6-phenyl-5-(1-piperazinyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 16 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 220967-40-8 CAPLUS
 CN 3(2H)-Pyridazinone, 6-(3,4-dimethoxyphenyl)-5-(4-phenyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 220967-42-0 CAPLUS
 CN 3(2H)-Pyridazinone, 6-(3,4-dimethoxyphenyl)-5-[4-(2-methoxyphenyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 17 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1997-005157 CAPLUS
 DOCUMENT NUMBER: 128:136324

TITLE: Pyridazine derivatives. XIV. Study of the vasorelaxant action of 6-aryl-5-piperidino-3-hydrazinopyridazines in isolated rat thoracic aorta: comparison with hydralazine

AUTHOR(S): Campos-Tomil, M.; Estevez, I.; Ravina, E.; Orallo, F.
 CORPORATE SOURCE: DEPARTAMENTO DE FARMACOLOGIA, FACULTAD DE FARMACIA, UNIVERSIDAD DE SANTIAGO DE COMPOSTELA, SANTIAGO DE COMPOSTELA, E-15706, Spain

SOURCE: General Pharmacology (1998), 30(2), 201-207
 CODEN: GEPHDZ; ISSN: 0306-3623

PUBLISHER: Elsevier Science Inc.
 DOCUMENT TYPE: Journal


LANGUAGE: English

AB 1. For several years we have been working on the synthesis of modified hydrazinopyridazines which have proved to possess remarkable vasorelaxant and antihypertensive activity. We now report the vasodilator effects of three novel 6-aryl-5-piperidino-3-hydrazinopyridazines, structurally related to the well-known antihypertensive drug hydralazine. 2. Hydralazine and the new hydrazinopyridazines relaxed in concentration-dependent and non-specific way, the contractions elicited by noradrenaline or a high K⁺ concentration in rat aortic rings with or without endothelium. According to the IC50 (50% inhibitory concn.) values obtained, the vasorelaxant potency of the new compds. was greater than that of hydralazine. 3. In a Ca²⁺-free medium, the contractions provoked by noradrenaline or caffeine were significantly inhibited by the new hydrazinopyridazines and by hydralazine. 4. Hydralazine and the novel mols. did not significantly modify basal, noradrenaline- or K⁺-induced 45Ca²⁺ uptake. 5. These results suggest that these hydrazinopyridazines have an endothelium-independent vasorelaxant activity greater than that of hydralazine in isolated rat aortic rings, which seems not to be mediated by a blockade of transmembrane Ca²⁺ movements through specific channels. This effect could be due, at least in part, to an intracellular mechanism of action.


IT 202325-47-1 202325-48-2 202325-49-3

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
 (vasorelaxant action of 6-aryl-5-piperidino-3-hydrazinopyridazines in isolated rat thoracic aorta and comparison with hydralazine)


RN 202325-47-1 CAPLUS
 CN 3(2H)-Pyridazinone, 6-phenyl-5-(1-piperidinyl)-, hydrazone (9CI) (CA INDEX NAME)



L4 ANSWER 17 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 202325-48-2 CAPLUS
 CN 3(2H)-Pyridazinone, 6-(4-methoxyphenyl)-5-(1-piperidinyl)-, hydrazone (9CI) (CA INDEX NAME)



RN 202325-49-3 CAPLUS
 CN 3(2H)-Pyridazinone, 6-(3,4-dimethoxyphenyl)-5-(1-piperidinyl)-, hydrazone (9CI) (CA INDEX NAME)



REFERENCE COUNT: 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 18 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1996-294193 CAPLUS

DOCUMENT NUMBER: 125:58060

TITLE: Synthesis of functionalized phenolic derivatives via the benzannulation of dienylketenes formed by a thermal Wolff rearrangement of α -diazo- β -keto compounds

AUTHOR(S): Collomb, Didier; Deshayes, Christian; Douthieux, Alain
 CORPORATE SOURCE: Departement Biochimie, Institut National Sciences Appliquées, Villeurbanne, 69621, Fr.

SOURCE: Tetrahedron (1996), 52(19), 6665-6684

CODEN: TETRAB; ISSN: 0040-4020

PUBLISHER: Elsevier

DOCUMENT TYPE: Journal

LANGUAGE: English


AB Eleven conjugated dienyl α -diazo- β -keto derivs. were prepared from α,β -unsatd. carbonyl compds. Their thermolysis induced a Wolff rearrangement generating an intermediate dienylketene whose isomer having the required configuration of the internal double bond underwent a benzannulation to form the corresponding phenolic derivs. When γ -substituted by a methoxy group, both stereoisomers of the diazo compds. gave rise to the phenolic derivs. due to the reversible formation of an intermediate cyclobutane which permitted the isomerization of the nonproductive transient dienylketene into the productive one.

IT 177979-65-6P


RL: SPN (Synthetic preparation); PRRP (Preparation)
 (functionalized phenolic derivs. via benzannulation of dienylketenes formed by Wolff rearrangement of α -diazo- β -keto compds.)

RN 177979-65-6 CAPLUS

CN Phosphonic acid, [4-hydroxy-6-phenyl-5-(1-piperidinyl)-3-pyridazinyl]-, dimethyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 19 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1992:59299 CAPLUS
 DOCUMENT NUMBER: 116:59299
 TITLE: Synthesis and reactions of some new pyridazinones
 AUTHOR(S): Ismail, A. A.; Radwan, R.; Abdel Hamid, H. A.; Sayed, G. H.; Mohamed, S. M.
 CORPORATE SOURCE: Fac. Sci., Al-Azhar Univ. Girls, Cairo, Egypt
 SOURCE: Journal of the Chemical Society of Pakistan (1991), 13(2), 111-115
 CODEN: JCSPDF; ISSN: 0253-5106
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI




AB β -(P-chlorobenzyl)acrylic acid $\text{PCOOCH}_2\text{CHCOOCH}_2\text{H}$ ($\text{R}=\text{ClC}_6\text{H}_4$) reacts with 3-methyl-1-phenyl-2-pyrazolin-5-one to give the adduct I. Reactions of I with hydrazine hydrate and phenylhydrazine afford the corresponding 4-pyrazolinononylpyridazinones II ($\text{R}^1 = \text{H, Ph}$). Reactions of 4-pyrazolinononylpyridazinone II ($\text{R}^1 = \text{H}$) with dimethylsulfate, diethylsulfate, Et bromosuccinate, benzenesulfonyl chloride, anisaldehyde, phenylmagnesium bromide and bromine-acetic acid mixture have been described. Reaction of II ($\text{R}^1 = \text{H}$) with POCl_3 yield the chloro derivative III. The behavior of the III towards sodium methoxide, hydrazine hydrate, anthranilic acid and sodium azide has been investigated.

IT 138560-64-2P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)


RN 138560-64-2 CAPLUS

CN Pyridazine, 6-(4-chlorophenyl)-4-(3-methyl-1,5-diphenyl-1H-pyrazol-4-yl)-3-phenyl- (9CI) (CA INDEX NAME)



L4 ANSWER 20 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1991:143314 CAPLUS
 DOCUMENT NUMBER: 114:143314
 TITLE: Pyridazine derivatives. IX. Synthesis of 2H-pyridazin-3-ones with arylpiperazinyl groups
 AUTHOR(S): Revina, Enrique; Teran, Carmen; Santana, Lourdes;
 Garcia, Neftali; Estevez, Isabel
 CORPORATE SOURCE: Fac. Pharm., Univ. Santiago, Santiago de Compostela,
 15706, Spain
 SOURCE: Heterocycles (1990), 31(11), 1967-74
 CODEN: HTCYAM; ISSN: 0385-5414
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 114:143314
 GI




AB 2H-Pyridazin-3-ones I ($\text{R} = \text{Ph}$, 2-furyl) were prepared. 6-Phenyl-5-(N4-acyloyl-N1-piperazinyl)-2H-pyridazin-3-ones were obtained by nucleophilic substitution of the chlorine atom of 6-phenyl-5-chloro-2H-pyridazin-3-one II or alternatively, by acylation of N1-piperazinyl-2H-pyridazin-3-one. Also, 6-phenyl-5-(N4-acyloyl-N1-piperazinylmethyl)-2H-pyridazin-3-ones (III) were prepared by displacement of the bromine in 6-phenyl-5-bromomethyl-2H-pyridazin-3-one (IV).

IT 132814-16-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and acylation of, with benzoyl or furanyl chloride)

RN 132814-16-5 CAPLUS

CN 3(2H)-Pyridazinone, 6-phenyl-5-(1-piperazinyl)- (9CI) (CA INDEX NAME)




IT 132814-12-1P 132814-13-2P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, as potential antihypertensive agent)

Habte

L4 ANSWER 19 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


L4 ANSWER 20 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 132814-12-1 CAPLUS
 CN Piperazine, 1-benzoyl-4-(1,6-dihydro-6-oxo-3-phenyl-4-pyridazinyl)- (9CI)
 (CA INDEX NAME)



RN 132814-13-2 CAPLUS


CN Piperazine, 1-(1,6-dihydro-6-oxo-3-phenyl-4-pyridazinyl)-4-(2-furanylcarbonyl)- (9CI) (CA INDEX NAME)



09/11/2006


L4 ANSWER 21 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1990:179002 CAPLUS
 DOCUMENT NUMBER: 112:179002
 TITLE: 5-(1H-Imidazol-1-yl)-3(2H)-pyridazinone derivatives as antithrombotics and medicinal fungicides
 INVENTOR(S): Shimamura, Hiroshi; Kosegi, Koji; Yaginuma, Hideya
 PATENT ASSIGNEE(S): Morishita Pharmaceutical Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 6 pp.
 CODEN: JIDCAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 01258671	A2	19891016	JP 1987-304986	19871201
PRIORITY APPLN. INFO.:			JP 1987-304986	19871201
OTHER SOURCE(S):	MARPAT	112:179002		
GI				




AB The title compds. I [R1 = H, Cl-14 alkyl, cinnamyl, naphthylmethyl, (halo-substituted) benzyl or phenoxethyl; R2 = H, 1H-imidazol-1-yl; R3 = H, (halo-substituted) phenyl] and their acid salts are prepared. Thus, a solution containing 5-chloro-6-phenyl-3(2H)-pyridazinone and imidazole in DMF was stirred 4 h at 140° to give 63% I (R1 = R2 = H, R3 = Ph) (II). II in vitro exhibited IC50 of 46.8 μM and 125.3 μM for arachidonic acid- and collagen-induced aggregation in rabbit blood, resp., vs. >155 and >448, resp., for aspirin. A tablet was prepared from II 50, lactose 200, crystalline cellulose 40, and Mg stearate 5 mg.
 IT 126428-66-8P, 5-(1H-Imidazol-1-yl)-6-phenyl-3(2H)-pyridazinone
 126428-67-9P 126461-33-4P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, as antithrombotic and medicinal fungicide)
 RN 126428-66-8 CAPLUS
 CN 3(2H)-Pyridazinone, 5-(1H-imidazol-1-yl)-6-phenyl- (9CI) (CA INDEX NAME)


L4 ANSWER 21 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 126428-67-9 CAPLUS
 CN 3(2H)-Pyridazinone, 6-(4-chlorophenyl)-5-(1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)



RN 126461-33-4 CAPLUS
 CN 3(2H)-Pyridazinone, 6-(2,4-dichlorophenyl)-5-(1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)




L4 ANSWER 22 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1987:213879 CAPLUS
 DOCUMENT NUMBER: 106:213879
 TITLE: Pyrazolo[1',5':1,6]pyrimido[4,5-d]pyridazin-7(8H)-one: a new heterocyclic ring system from isoxazolopyridazinones
 AUTHOR(S): Dal Piaz, Vittorio; Ciclani, Giovanna; Chimichi, Stefano
 CORPORATE SOURCE: Dip. Sci. Farm., Univ. Firenze, Florence, I-50121, Italy
 SOURCE: Heterocycles (1986), 24(11), 3143-8
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 106:213879
 GI





AB Treatment of isoxazolopyridazinones I (R = H, Me; R1 = Me, Ph; R2 = Ph, 4-ClC6H4) with N2H4 afforded the pyrazole derivs. II which were converted in high yields into the new pyrazolopyrimidopyridazinones III by ring-closure with Ac2O.
 IT 108311-75-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactants or reagent)
 (preparation and cyclocondensation of, with acetic anhydride)
 RN 108311-75-7 CAPLUS
 CN 3(2H)-Pyridazinone, 4-amino-6-phenyl-5-(5-phenyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)

L4 ANSWER 22 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L4 ANSWER 23 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1986-626436 CAPLUS
 DOCUMENT NUMBER: 105:226436
 TITLE: Studies on some β -aryl- α -(1,3-disubstituted 5-oxo-2-pyrazolin-4-yl)propionic acids
 AUTHOR(S): Sayed, G. H.; Ismail, A. A.; Hashem, Z.
 CORPORATE SOURCE: Fac. Sci., Ain Shams Univ., Cairo, Egypt
 SOURCE: Egyptian Journal of Chemistry (1985), Volume Date 1984, 27(6), 757-65
 CODEN: EGJCA3; ISSN: 0367-0422
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 105:226436
 GI


L4 ANSWER 23 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




AB Addition of pyrazolinones I (R = Ph, R1 = Me, Ph) to arylacrylic acids II (R2 = R3 = Cl; R2 = H, R3 = Br) gave adducts III. Cyclocondensation of III with RN4NH2 (R4 = H, Ph) gave pyridazinones IV. In vitro antibacterial screening of III (R = R1 = Ph; R2 = R3 = Cl; R2 = H, R3 = Br) showed substantial activity against gram-pos. and gram-neg. bacteria.

IT 94051-61-3
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (Preparation of)
 RN 94051-61-3 CAPLUS
 CN 3H-Pyrazol-3-one, 4-[6-(4-bromophenyl)-3-phenyl-4-pyridazinyl]-2,4-dihydro-5-methyl-2-phenyl- (9CI) (CA INDEX NAME)

L4 ANSWER 24 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1985-571690 CAPLUS
 DOCUMENT NUMBER: 103:171690
 TITLE: Pyridazine derivatives. III. Synthesis and antihypertensive activity of 6-phenyl-5-amino-3-hydrazinopyridazines
 AUTHOR(S): Garcia, G. J.; Ravina, E.; Santana, L.; Orallo, F.; Calleja, J. M.
 CORPORATE SOURCE: Dept. Quim. Org. Quim. Farm., Univ. Santiago, Santiago, Spain
 SOURCE: Anales de la Real Academia de Farmacia (1985), 61(1), 23-31
 CODEN: ARAFAY; ISSN: 0034-0618
 DOCUMENT TYPE: Journal
 LANGUAGE: Spanish
 OTHER SOURCE(S): CASREACT 103:171690
 GI




AB The title compds. were prepared by multistep syntheses beginning with mucochloric acid [87-56-9]. Mucochloric acid was reacted with benzene [71-43-2] and AlCl3 to form γ -phenyl- α , β -dichloro- Δ ₄, β -crotonolactone [72057-85-3] which, after treatment with NH4 in boiling EtOH, yielded 6-phenyl-5-chloro-3(2H)-pyridazinone [51660-09-3]. Reacting the latter with 3 different cyclamines yielded three 6-phenyl-5-amino-3(2H)-pyridazinones. These, when reacted with P2S5 plus NH4 or POCl3 plus NH4 yielded 3 6-phenyl-5-amino-3-hydrazinopyridazines. Of these 3 compds., the strongest antihypertensive activity (comparable with hydralazine) in rats was displayed by 6-phenyl-5-(N-4-phenylpiperazinyl)-3-hydrazinopyridazine (I) [98896-19-6].
 IT 98896-19-6; 98896-21-0P; 98896-22-1P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); TBU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses); (preparation and antihypertensive activity of)
 RN 98896-19-6 CAPLUS
 CN 3(2H)-Pyridazinone, 6-phenyl-5-(4-phenyl-1-piperazinyl)-, hydrazone (9CI) (CA INDEX NAME)




RN 98896-21-0 CAPLUS
 CN 3(2H)-Pyridazinone, 5-[4-(2-methoxyphenyl)-1-piperazinyl]-6-phenyl-,

Habte


L4 ANSWER 24 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 hydrazone (9CI) (CA INDEX NAME)



RN 98896-22-1 CAPLUS
 3(2H)-Pyridazinone, 5-(4-morpholinyl)-6-phenyl-, hydrazone (9CI) (CA INDEX NAME)




IT 98896-29-8P; 98896-30-1P; 98896-31-2P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and hydrazino derivatization of)
 RN 98896-29-8 CAPLUS
 CN 3(2H)-Pyridazinone, 5-[4-(2-methoxyphenyl)-1-piperazinyl]-6-phenyl- (9CI) (CA INDEX NAME)




RN 98896-30-1 CAPLUS
 3(2H)-Pyridazinone, 6-phenyl-5-(4-phenyl-1-piperazinyl)- (9CI) (CA INDEX

09/11/2006


L4 ANSWER 24 OF 30 CAPIUS COPYRIGHT 2006 ACS on STN (Continued)
NAME)



RN 98896-31-2 CAPIUS
CN 3(2H)-Pyridazinone, 5-(4-morpholinyl)-6-phenyl- (9CI) (CA INDEX NAME)




IT 98896-23-2P 98896-24-3P 98896-25-4P
98896-26-5P 98896-27-6P 98896-28-7P
RN: PCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation and reaction of, with hydrazine)
RN 98896-23-2 CAPIUS
CN Pyridazine, 6-chloro-4-[4-(2-methoxyphenyl)-1-piperazinyl]-3-phenyl- (9CI) (CA INDEX NAME)




RN 98896-24-3 CAPIUS
CN Pyridazine, 6-chloro-3-phenyl-4-(4-phenyl-1-piperazinyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 24 OF 30 CAPIUS COPYRIGHT 2006 ACS on STN (Continued)




RN 98896-25-4 CAPIUS
CN Morpholine, 4-(6-chloro-3-phenyl-4-pyridazinyl)- (9CI) (CA INDEX NAME)



RN 98896-26-5 CAPIUS
CN 3(2H)-Pyridazinethione, 5-[4-(2-methoxyphenyl)-1-piperazinyl]-6-phenyl- (9CI) (CA INDEX NAME)




RN 98896-27-6 CAPIUS
CN 3(2H)-Pyridazinethione, 6-phenyl-5-(4-phenyl-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 98896-28-7 CAPIUS
CN 3(2H)-Pyridazinethione, 5-(4-morpholinyl)-6-phenyl- (9CI) (CA INDEX NAME)

L4 ANSWER 24 OF 30 CAPIUS COPYRIGHT 2006 ACS on STN (Continued)




L4 ANSWER 25 OF 30 CAPIUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1985-24542 CAPIUS
DOCUMENT NUMBER: 102:24542
TITLE: Synthesis of some new β -acyl- α -[4-(1,3-disubstituted-2-pyrazolin-5-one)]propionic acids and 4-pyrazolinylpyridazinones and the study of their antibacterial activities
AUTHOR(S): Sayed, G. H.; Ismail, A. A.; Hashem, Z.
CORPORATE SOURCE: Fac. Sci., Ain Shams Univ., Cairo, Egypt
SOURCE: Journal of the Chemical Society of Pakistan (1984), 6(2), 95-101
DOCUMENT TYPE: CODEN: JCSPDF; ISSN: 0253-5106
LANGUAGE: English
GI




AB RCOCH₂CH(CO₂H)-C(=O)-N(R)-C(=O)-N(R)-C(=O)-R₁ react with 1,3-disubstituted-2-pyrazolin-5-ones in dry CGH₆ to give β -acyl- α -[4-(1,3-disubstituted-2-pyrazolin-5-one)]propionic acids (I, R₁ = Me, Ph). Esterification of I (R = 3,4-C₁₂CGH₃, R₁ = Ph) with CH₂N₂ gives the corresponding Me ester. Reactions of I with N₂H₄ and PhNH₂H₂ afford the 4-pyrazolinylpyridazinones II (R₂ = H, Ph). Dehydration of I yielded the butenolides, which undergo ring opening reaction with amines to give the N-alkylamides of I. Reactions of II (R₂ = H) with 4-MeOC₆H₄CH₂Cl, BrCH₂CO₂Et, Et₂SO₄, and Grignard reagents have also been described. The in vitro antibacterial screening reveals substantial activities against Gram-pos. and Gram-neg. bacteria for I (R = 4-BrCGH₄, 3,4-C₁₂CGH₃, R₁ = Ph) while I (R₁ = Me) and II (R = 3,4-C₁₂CGH₃, R₂ = Me, R₂ = H) are inactive.


IT 94051-61-3P
RN: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 94051-61-3 CAPIUS
CN 3H-Pyrazol-3-one, 4-[6-(4-bromophenyl)-3-phenyl-4-pyridazinyl]-2,4-dihydro-5-methyl-2-phenyl- (9CI) (CA INDEX NAME)



L4 ANSWER 26 OF 30 CAPIUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1967-482185 CAPIUS
 DOCUMENT NUMBER: 67-82185
 TITLE: Compounds with antineoplastic action. XVIII. Some 4-substituted 3-(*p*-methoxyphenyl)-6-pyridazinones
 AUTHOR(S): Zikan, Viktor; Semonsky, Miroslav
 CORPORATE SOURCE: Vyskumny Ustav Farm. Biochem., Prague, Czech.
 SOURCE: Collection of Czechoslovak Chemical Communications (1967), 23(6), 2374-7
 CODEN: CCCAK1 ISSN: 0010-0765
 DOCUMENT TYPE: Journal
 LANGUAGE: German
 GI For diagram(s), see printed CA Issue.
 AB cf. CA 66: 95001a. A mixture of 11.6 g. *p*-MeOC₆H₄CBr₂CHCO₂Me (I) or its cyclic form (II), 6.2 g. N₂H₄ hydrate, and 50 ml. EtOH was stirred at room temperature 40 hrs. to give 90% III, m. 228-9° (EtOH). A mixture of 2.32 g. II and 3.72 g. N₂H₄ hydrate heated 3 hrs. at 115-20° and 3 hrs. at 130-5° gave 100% IV, m. 230-2° (aqueous EtOH), while with I the yield of IV was only 58%. A mixture of 15.2 g. IV and 34.7 g. BzH heated in a sealed tube 1 hrs. at 140° gave 81% V, m. 260-1° (MeOH). Similarly, IV and *p*-MeOC₆H₄CHO gave 79% VI, m. 243-4° (MeOH). VII (1.4 g.) refluxed with 5 ml. CS₂HON or morpholine 7 hrs. gave 98% VII, m. 212-14° (EtOH), or 86% VIII, m. 268-9° (aqueous EtOH), resp. None of the above pyridazinones III-VIII was more active than the parent I.
 IT 15904-59-3P 15904-60-6P
 RL: 5PN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 15904-59-3 CAPIUS
 CN 3(2H)-Pyridazinone, 6-(4-methoxyphenyl)-5-(1-piperidinyl)- (9CI) (CA INDEX NAME)




RN 15904-60-6 CAPIUS
 CN 3(2H)-Pyridazinone, 6-(4-methoxyphenyl)-5-morpholino- (8CI) (CA INDEX NAME)




L4 ANSWER 27 OF 30 CAPIUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1966-499389 CAPIUS
 DOCUMENT NUMBER: 65-99389
 ORIGINAL REFERENCE NO.: 65:18599b, 18600-a-c
 TITLE: 3-Phenyl-4-piperazinylcinnolinines
 INVENTOR(S): Lowrie, Harman S.
 PATENT ASSIGNEE(S): G.D. Seacle and Co.
 SOURCE: 3 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: Unavailable
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3272818	-----	19660913	US 1964-382341	19640713
AB	For diagram(s), see printed CA Issue.			
AB	Title compds. (I), where R and R ₁ are H, F, Cl, Br, I, and Cl-6 alkyl and alkoxy, and R ₂ is H, Cl-6 alkyl, alkanoyl, (lower alkoxy)carbonyl, hydroxethyl, Ph, and PhCH ₂ , are prepared by the reaction of a halo-substituted phenylcinnoline with a piperazine or an N-substituted piperazine. E.g., a mixture of 4 parts 4-chloro-3-phenylcinnoline, 1 part Cu powder and 20 parts (volume) 1-methylpiperazine was refluxed 1.5 hrs. cooled, diluted with Et ₂ O, and filtered. The filtrate was washed with dilute KOH, the ether solution extracted with dilute HCl, and the extract was made alkaline, extracted with Et ₂ O, and dried with saturated NaCl solution and then with anhyd. K ₂ CO ₃ . The solvent was evaporated and the residue crystallized from hexane to give I (R = R ₁ H, R ₂ = Me), m. 128-29°. Also prepared were the I in the table. R, R ₁ , R ₂ , M.p.; 4-Cl, H, Me, 151-3'; 4-Me, H, Me, -; 4-OH, H, Me, 156-7'; H, H, CH ₂ CH ₂ OH, 170-3'; H, H, H, 171-3'; H, H, Ac, 209-10'; H, H, CO ₂ Et, 128-9'; H, H, Ph, 181-2'; H, H, CH ₂ Ph, 110-11'; The growth of certain bacteria is inhibited by I.			
IT	6450-85-7, Cinnoline, 4-(4-methyl-1-piperazinyl)-3-phenyl-6482-16-2, Cinnoline, 3-phenyl-4-(1-piperazinyl)-10001-21-5, Cinnoline, 3-(p-chlorophenyl)-4-(4-methyl-1-piperazinyl)-10001-22-6, Cinnoline, 3-(<i>p</i> -methoxyphenyl)-4-(4-methyl-1-piperazinyl)-10001-23-7, 1-Piperazineethanol, 4-(3-phenyl-4-cinnolinyl)-10001-25-9, Piperazine, 1-acetyl-4-(3-phenyl-4-cinnolinyl)-10001-26-0, 1-Piperazinecarboxylic acid, 4-(3-phenyl-4-cinnolinyl)-, ethyl ester 10001-27-1, Cinnoline, 3-phenyl-4-(4-phenyl-1-piperazinyl)-10001-28-2, Cinnoline, 4-(4-benzyl-1-piperazinyl)-3-phenyl- (preparation of)			
RN	6450-85-7 CAPIUS			
CN	Cinnoline, 4-(4-methyl-1-piperazinyl)-3-phenyl- (7CI, 8CI, 9CI) (CA INDEX NAME)			


L4 ANSWER 27 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 6482-16-2 CAPLUS
 CN Cinnoline, 3-phenyl-4-(1-piperazinyl)- (7CI, 8CI, 9CI) (CA INDEX NAME)




RN 10001-21-5 CAPLUS
 CN Cinnoline, 3-(p-chlorophenyl)-4-(4-methyl-1-piperazinyl)- (7CI, 8CI) (CA INDEX NAME)




RN 10001-22-6 CAPLUS
 CN Cinnoline, 3-(p-methoxyphenyl)-4-(4-methyl-1-piperazinyl)- (7CI, 8CI) (CA INDEX NAME)


L4 ANSWER 27 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 10001-27-1 CAPLUS
 CN Cinnoline, 3-phenyl-4-(4-phenyl-1-piperazinyl)- (7CI, 8CI) (CA INDEX NAME)




RN 10001-28-2 CAPLUS
 CN Cinnoline, 4-(4-benzyl-1-piperazinyl)-3-phenyl- (7CI, 8CI) (CA INDEX NAME)




L4 ANSWER 27 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 10001-23-7 CAPLUS
 CN 1-Piperazineethanol, 4-(3-phenyl-4-cinnolinyl)- (7CI, 8CI) (CA INDEX NAME)



RN 10001-25-9 CAPLUS
 CN Piperazine, 1-acetyl-4-(3-phenyl-4-cinnolinyl)- (7CI, 8CI) (CA INDEX NAME)



RN 10001-26-0 CAPLUS
 CN 1-Piperazinecarboxylic acid, 4-(3-phenyl-4-cinnolinyl)-, ethyl ester (7CI, 8CI) (CA INDEX NAME)

L4 ANSWER 28 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 19661465520 CAPLUS

DOCUMENT NUMBER: 65:65520

ORIGINAL REFERENCE NO.: 65:12203b-c

TITLE: Synthesis of potential antineoplastic agents. XV. Some 1,4-bisamides of 1,2,3,4-tetrahydroquinolines.

AUTHOR(S): Schuyler, Peter; Popp, Frank D.; Noble, Adrienne Catala; Alwan, Ozu W.; Masters, Barry R.

CORPORATE SOURCE: Clarkson Coll. of Technol., Potsdam, NY

SOURCE: Journal of Medicinal Chemistry (1966), 9(5), 704-7

CODEN: JMCMAR ISSN: 0022-2623

DOCUMENT TYPE: Journal

LANGUAGE: English

AB cf. CA 65, 5459c. A number of Cl-containing and unsatd. 1,4-bisamides have been

prepared from 1,2,3,4-tetrahydroquinolines and from substituted 1,2,3,4-tetrahydroquinolines. Although many of these amides are active against KB cell culture, they are inactive against animal tumors. A number of related amides were also prepared from 1,2,3,4-tetrahydroquinoline and 1,2,3,4-tetrahydroisoquinoline.

IT 6450-85-7, Cinnoline, 4-(4-methyl-1-piperazinyl)-3-phenyl-

6482-16-2, Cinnoline, 3-phenyl-4-(1-piperazinyl)-

10001-21-5, Cinnoline, 3-(p-chlorophenyl)-4-(4-methyl-1-

piperazinyl)- 10001-22-6, Cinnoline, 3-(p-methoxyphenyl)-4-(4-

methyl-1-piperazinyl)- 10001-23-7, 1-Piperazineethanol,

4-(3-phenyl-4-cinnolinyl)- 10001-25-9, Piperazine,

1-acetyl-4-(3-phenyl-4-cinnolinyl)- 10001-27-1, Cinnoline,

3-phenyl-4-(4-phenyl-1-piperazinyl)- 10001-28-2, Cinnoline,

4-(4-benzyl-1-piperazinyl)-3-phenyl- 10579-35-8, Cinnoline,

4-(4-nitroso-1-piperazinyl)-3-phenyl- 10579-38-1, Piperazine,

1-(p-chlorobenzoyl)-4-(3-phenyl-4-cinnolinyl)- 10604-38-3,


Cinnoline, 3-phenyl-4-piperidino- 10604-48-5, Cinnoline,

4-[4-(2-dimethylamino)ethyl]piperidino)-3-phenyl-

(preparation of)


RN 6450-85-7 CAPLUS

CN Cinnoline, 4-(4-methyl-1-piperazinyl)-3-phenyl- (7CI, 8CI, 9CI) (CA INDEX NAME)




RN 6482-16-2 CAPLUS
 CN Cinnoline, 3-phenyl-4-(1-piperazinyl)- (7CI, 8CI, 9CI) (CA INDEX NAME)


L4 ANSWER 28 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 10001-21-5 CAPLUS
 CN Cinnoline, 3-(p-chlorophenyl)-4-(4-methyl-1-piperazinyl)- (7CI, 8CI) (CA INDEX NAME)




RN 10001-22-6 CAPLUS
 CN Cinnoline, 3-(p-methoxyphenyl)-4-(4-methyl-1-piperazinyl)- (7CI, 8CI) (CA INDEX NAME)




RN 10001-23-7 CAPLUS
 CN 1-Piperazineethanol, 4-(3-phenyl-4-cinnolinyl)- (7CI, 8CI) (CA INDEX NAME)

L4 ANSWER 28 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 10579-35-8 CAPLUS
 CN Cinnoline, 4-(4-nitro-1-piperazinyl)-3-phenyl- (7CI, 9CI) (CA INDEX NAME)




RN 10579-38-1 CAPLUS
 CN Piperazine, 1-(p-chlorobenzoyl)-4-(3-phenyl-4-cinnolinyl)- (7CI, 8CI) (CA INDEX NAME)


L4 ANSWER 28 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 10001-25-9 CAPLUS
 CN Piperazine, 1-acetyl-4-(3-phenyl-4-cinnolinyl)- (7CI, 8CI) (CA INDEX NAME)




RN 10001-27-1 CAPLUS
 CN Cinnoline, 3-phenyl-4-(4-phenyl-1-piperazinyl)- (7CI, 8CI) (CA INDEX NAME)




RN 10001-28-2 CAPLUS
 CN Cinnoline, 4-(4-benzyl-1-piperazinyl)-3-phenyl- (7CI, 8CI) (CA INDEX NAME)


L4 ANSWER 28 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 10604-38-3 CAPLUS
 CN Cinnoline, 3-phenyl-4-(1-piperidinyl)- (9CI) (CA INDEX NAME)



RN 10604-48-5 CAPLUS
 CN Cinnoline, 4-[4-(2-(dimethylamino)ethyl)piperidino]-3-phenyl- (7CI, 8CI) (CA INDEX NAME)




L4 ANSWER 29 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 19661465519 CAPLUS
 DOCUMENT NUMBER: 65:65519
 ORIGINAL REFERENCE NO.: 65:12203b
 TITLE: 3-Phenylcinnolines. II. Preparation of 4-amino derivatives
 AUTHOR(S): Lowrie, Harman S.
 CORPORATE SOURCE: Div. of Chem. Res., G. D. Searle & Co., Chicago
 SOURCE: Journal of Medicinal Chemistry (1966), 9(5), 670-4
 CODEN: JMCMAR; ISSN: 0022-2623
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB cf. preceding abstract. The development of methods for converting 3-phenylcinnoline-4-carboxylic acids into the 4-hydroxy and 4-chloro analogs led to the preparation of 4-amino compds. which were examined for pharmacol. activity. 27 references.
 IT 6482-16-2, Cinnoline, 4-(4-methyl-1-piperazinyl)-3-phenyl-
 10001-21-5, Cinnoline, 3-(p-chlorophenyl)-4-(4-methyl-1-piperazinyl)-
 10001-22-6, Cinnoline, 3-(p-methoxyphenyl)-4-(4-methyl-1-piperazinyl)-
 10001-23-7, 1-Piperazineethanol,
 4-(3-phenyl-4-cinnolinyl)-10001-23-7, 1-Acetyl-4-(3-phenyl-4-cinnolinyl)-10001-25-9, Piperazine,
 3-phenyl-4-(4-phenyl-1-piperazinyl)-10001-28-2, Cinnoline,
 4-(4-benzyl-1-piperazinyl)-3-phenyl-10579-35-8, Cinnoline,
 4-(4-nitroso-1-piperazinyl)-3-phenyl-10579-38-1, Piperazine,
 1-(p-chlorobenzoyl)-4-(3-phenyl-4-cinnolinyl)-10604-38-3,
 Cinnoline, 3-phenyl-4-piperidino-10604-48-5, Cinnoline,
 4-[4-(2-dimethylamino)ethyl]piperidino-3-phenyl-
 (preparation of)
 RN 6450-85-7 CAPLUS
 CN Cinnoline, 4-(4-methyl-1-piperazinyl)-3-phenyl- (7CI, 8CI, 9CI) (CA INDEX NAME)




RN 6482-16-2 CAPLUS
 CN Cinnoline, 3-phenyl-4-(1-piperazinyl)- (7CI, 8CI, 9CI) (CA INDEX NAME)


L4 ANSWER 29 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 10001-21-5 CAPLUS
 CN Cinnoline, 3-(p-chlorophenyl)-4-(4-methyl-1-piperazinyl)- (7CI, 8CI) (CA INDEX NAME)




RN 10001-22-6 CAPLUS
 CN Cinnoline, 3-(p-methoxyphenyl)-4-(4-methyl-1-piperazinyl)- (7CI, 8CI) (CA INDEX NAME)




RN 10001-23-7 CAPLUS
 CN 1-Piperazineethanol, 4-(3-phenyl-4-cinnolinyl)- (7CI, 8CI) (CA INDEX NAME)


L4 ANSWER 29 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 10001-25-9 CAPLUS
 CN Piperazine, 1-acetyl-4-(3-phenyl-4-cinnolinyl)- (7CI, 8CI) (CA INDEX NAME)




RN 10001-27-1 CAPLUS
 CN Cinnoline, 3-phenyl-4-(4-phenyl-1-piperazinyl)- (7CI, 8CI) (CA INDEX NAME)




RN 10001-28-2 CAPLUS
 CN Cinnoline, 4-(4-benzyl-1-piperazinyl)-3-phenyl- (7CI, 8CI) (CA INDEX NAME)


L4 ANSWER 29 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 10579-35-8 CAPLUS
 CN Cinnoline, 4-(4-nitroso-1-piperazinyl)-3-phenyl- (7CI, 9CI) (CA INDEX NAME)




RN 10579-38-1 CAPLUS
 CN Piperazine, 1-(p-chlorobenzoyl)-4-(3-phenyl-4-cinnolinyl)- (7CI, 8CI) (CA INDEX NAME)



L4 ANSWER 29 OF 30 CAPIUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 10604-38-3 CAPIUS
 CN Cinnoline, 3-phenyl-4-(1-piperidinyl)- (9CI) (CA INDEX NAME)



RN 10604-48-5 CAPIUS
 CN Cinnoline, 4-[4-[2-(dimethylamino)ethyl]piperidino]-3-phenyl- (7CI, 8CI) (CA INDEX NAME)



L4 ANSWER 30 OF 30 CAPIUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1966-465518 CAPIUS
 DOCUMENT NUMBER: 65-65518
 ORIGINAL REFERENCE NO.: 65-12203a-b
 TITLE: 3-phenylcinnolines. I. Some reactions and derivatives of 3-phenylcinnoline-4-carboxylic acids


AUTHOR(S): Lowrie, Harman S.
 CORPORATE SOURCE: Div. of Chem. Res., G. D. Searle & Co., Chicago
 SOURCE: Journal of Medicinal Chemistry (1966), 9(5), 664-9
 CODEN: JMCNAU ISSN: 0022-2623

DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 65-65518

AB A series of amide, hydrazide, and ester derivs. of the title acids and 2 phenylbutazone analogs of 3-phenylcinnoline were prepared. These were examined


for pharmacol. activity. 21 references.
 IT 6450-85-7, Cinnoline, 4-(4-methyl-1-piperazinyl)-3-phenyl-
 6452-16-2, Cinnoline, 3-phenyl-4-(1-piperazinyl)-
 10001-21-5, Cinnoline, 3-(p-chlorophenyl)-4-(4-methyl-1-piperazinyl)- 10001-22-6, Cinnoline, 3-(p-methoxyphenyl)-4-(4-methyl-1-piperazinyl)- 10001-23-7, 1-(1-piperazineethanol,
 4-(3-phenyl-4-cinnolinyl)- 10001-25-9, 1-piperazine,
 1-acetyl-4-(3-phenyl-4-cinnolinyl)- 10001-26-0,
 1-Piperazinecarboxylic acid, 4-(3-phenyl-4-cinnolinyl)-, ethyl ester
 10001-27-1, Cinnoline, 3-phenyl-4-(4-phenyl-1-piperazinyl)-
 10001-28-2, Cinnoline, 4-(4-phenyl-1-piperazinyl)-3-phenyl-
 10579-38-1, Piperazine, 1-(p-chlorophenyl)-4-(3-phenyl-4-cinnolinyl)- 10604-38-3, Cinnoline, 3-phenyl-4-piperidino-
 10604-48-5, Cinnoline, 4-[4-[2-(dimethylamino)ethyl]piperidino]-3-phenyl-

(preparation of)
 RN 6450-85-7 CAPIUS
 CN Cinnoline, 4-(4-methyl-1-piperazinyl)-3-phenyl- (7CI, 8CI, 9CI) (CA INDEX NAME)




RN 6482-16-2 CAPIUS
 CN Cinnoline, 3-phenyl-4-(1-piperazinyl)- (7CI, 8CI, 9CI) (CA INDEX NAME)


L4 ANSWER 30 OF 30 CAPIUS COPYRIGHT 2006 ACS on STN (Continued)



RN 10001-21-5 CAPIUS
 CN Cinnoline, 3-(p-chlorophenyl)-4-(4-methyl-1-piperazinyl)- (7CI, 8CI) (CA INDEX NAME)




RN 10001-22-6 CAPIUS
 CN Cinnoline, 3-(p-methoxyphenyl)-4-(4-methyl-1-piperazinyl)- (7CI, 8CI) (CA INDEX NAME)




RN 10001-23-7 CAPIUS
 CN 1-Piperazineethanol, 4-(3-phenyl-4-cinnolinyl)- (7CI, 8CI) (CA INDEX NAME)


L4 ANSWER 30 OF 30 CAPIUS COPYRIGHT 2006 ACS on STN (Continued)



RN 10001-25-9 CAPIUS
 CN Piperazine, 1-acetyl-4-(3-phenyl-4-cinnolinyl)- (7CI, 8CI) (CA INDEX NAME)




RN 10001-26-0 CAPIUS
 CN 1-Piperazinecarboxylic acid, 4-(3-phenyl-4-cinnolinyl)-, ethyl ester (7CI, 8CI) (CA INDEX NAME)




RN 10001-27-1 CAPIUS
 CN Cinnoline, 3-phenyl-4-(4-phenyl-1-piperazinyl)- (7CI, 8CI) (CA INDEX NAME)


L4 ANSWER 30 OF 30 CAPIUS COPYRIGHT 2006 ACS on STN (Continued)



RN 10001-28-2 CAPIUS
 CN Cinnoline, 4-(4-benzyl-1-piperazinyl)-3-phenyl- (7CI, 8CI) (CA INDEX NAME)




RN 10579-35-8 CAPIUS
 CN Cinnoline, 4-(4-nitroso-1-piperazinyl)-3-phenyl- (7CI, 9CI) (CA INDEX NAME)




RN 10579-38-1 CAPIUS
 CN Piperazine, 1-(p-chlorobenzoyl)-4-(3-phenyl-4-cinnolinyl)- (7CI, 8CI) (CA INDEX NAME)


L4 ANSWER 30 OF 30 CAPIUS COPYRIGHT 2006 ACS on STN (Continued)



RN 10604-38-3 CAPIUS
 CN Cinnoline, 3-phenyl-4-(1-piperidinyl)- (9CI) (CA INDEX NAME)



RN 10604-48-5 CAPIUS
 CN Cinnoline, 4-(4-[2-(dimethylamino)ethyl]piperidino)-3-phenyl- (7CI, 8CI) (CA INDEX NAME)



L4 ANSWER 30 OF 30 CAPIUS COPYRIGHT 2006 ACS on STN (Continued)